The Westaim Corporation Reports 2020 Third Quarter Results

 The Westaim Corporation Reports 2020 Third Quarter Results

 Note: All dollar amounts in this press release are expressed in U.S. dollars, except as otherwise noted.

The financial results are reported under International Financial Reporting Standards, except as otherwise noted.

TORONTO–(BUSINESS WIRE)–
The Westaim Corporation (“Westaim” or the “Company”) (TSXV: WED) today announced its financial results for the third quarter ended September 30, 2020. Westaim recorded a net profit of $0.6 million (nil earnings per diluted share) and a net loss of $20.0 million ($0.14 loss per diluted share) for the three and nine months ended September 30, 2020, respectively, compared to a net profit of $3.7 million ($0.03 earnings per diluted share) and a net profit of $21.6 million ($0.15 earnings per diluted share) in the three and nine months ended September 30, 2019, respectively. Book value per share was $2.33 (C$3.10) at September 30, 2020, compared to $2.48 (C$3.22) at December 31, 2019.

Key Results for the three months ended September 30, 2020 (with comparisons to the same period in 2019) include:

  • HIIG: The fair value of HIIG increased $3.3 million in the quarter compared to $2.7 million. The underwriting result has improved from the prior period resulting in a total combined ratio of 96.3% compared to 99.3%. Underwriting actions taken by new management contributed to the gross written premium decreasing 17.8% in the quarter as HIIG re-underwrote some existing businesses, and exited underperforming businesses including monoline workers’ compensation and lawyers and insurance agent professional liability, while accelerating growth in other segments of the business. HIIG’s growth strategy is focused on the remaining businesses and new opportunities where HIIG, with its intermediaries, have specialty expertise and/or key relationships with the target customer base.
  • Arena FINCOs: The fair value of Arena FINCOs increased $0.4 million (+0.2% net return) in the quarter compared to $1.3 million (+0.9% net return). On September 29, 2020, Arena Finance II, LLC (“AFII”), one of the Arena FINCOs, secured a private placement of $45 million of 6.75% senior secured notes to improve net returns by leveraging invested assets. The net proceeds received from these notes will be used by the Arena FINCOs in accordance with their investment objectives.
  • Arena Investors: Westaim’s share of Arena Investors’ net loss in the quarter was $0.3 million compared to a net loss of $0.5 million. Arena Investors had an increase in revenue from higher incentive fees than the prior year by $1.3 million (Westaim’s share of the increase of $0.6 million). This increase in revenues was partially offset by higher expenses as the platform built was being completed.

“Our Q3 results underscore the “third inning” directional objectives shared with stakeholders in Westaim’s September 22nd, 2020 Investor Day. Within HIIG, Andrew Robinson’s laser focus on execution and achieving first quartile performance is starting to be reflected in our underwriting results.” said J. Cameron MacDonald, President and Chief Executive Officer of Westaim. “Industry conditions remain quite favourable for profitable growth with US composite insurance pricing up in excess of 10%, and as highlighted during the Investor Day, any business lines that do not achieve an acceptable return on invested capital will be corrected or culled. Importantly, Andrew continues to attract high quality professionals and pursue opportunities that collectively will contribute to our growth and results. We are excited about the trajectory of HIIG as we move into 2021.”

“Arena Investors achieved several key milestones in the third quarter. Firstly, we completed a $45 million non-recourse note issue at AFII, one of the Arena FINCOs, which is expected to accelerate our ability to enhance returns on our proprietary capital on a prudent basis. Secondly, Arena Investors continues to excel in delivering solid performance throughout a volatile period allowing the firm to be a recipient of four industry performance awards in 2020, including the Bloomberg Hedgeweek Multi-strategy Fund of the Year announced on October 26th. It is worth noting that since Arena’s 2015 inception, over 200 credits have been executed by the Arena team delivering cumulative gross returns to date of approximately $345 million. With four offices and a team of 61 around the globe, Arena is well positioned to provide investors diversified, non-correlated consistent returns. Lastly, as of November 1st, committed and invested assets under management has grown to $1.7B. We expect the positive inflow of AUM to continue, and look forward to delivering operating leverage in the business moving forward.”

Key Results for the nine months ending September 30, 2020 (with comparisons to the same period in 2019) include:

  • HIIG: Along with the purchase of $44.0 million of HIIG convertible preferred shares, the Company recorded a fair value decrease in HIIG of $14.7 million in the first nine months of 2020. This decrease included a reduction in the first quarter of $14.9 million from the change in the HIIG valuation multiple from 1.1X to 1.0X adjusted book value. HIIG’s underwriting results produced a combined ratio excluding LPT of 97.5% compared to 99.0%.
  • Arena FINCOs: The fair value of the Arena FINCOs decreased $1.6 million (-0.9% net return) over the first nine months of 2020 compared to an increase of $9.1 million (+5.6% net return). The net returns have been positive in the last two quarters after reporting a -2.0% net return in the first quarter of 2020.
  • Arena Investors: Westaim’s share of Arena Investors’ net loss for the first nine months of 2020 was $1.5 million compared to a net profit of $0.2 million. Arena Investors had a decrease in revenue from lower incentive fees than the prior year by $3.6 million (Westaim’s share of the decrease of $1.8 million).

This press release should be read in conjunction with the Company’s unaudited interim financial statements, accompanying notes and Management Discussion and Analysis (“MD&A”) for the three and nine months ended September 30, 2020 and with our annual Consolidated Financial Statements and MD&A for the year ended December 31, 2019, which can be found on SEDAR at www.sedar.com and on the Company’s website www.westaim.com.

Non-GAAP Financial Measures

Westaim uses both International Financial Reporting Standards (“IFRS”) and non-generally accepted accounting principles (“non-GAAP”) measures to assess performance. The Company cautions readers about non-GAAP measures that do not have a standardized meaning under IFRS and are unlikely to be comparable to similar measures used by other companies. Book value per share is a non-GAAP measure. Readers are urged to review Section 15 Non-GAAP Measures in Westaim’s Management’s Discussion and Analysis in respect of its unaudited consolidated financial statements for the three and nine months ended September 30, 2020 and 2019 (the “MD&A”) for additional disclosure regarding these measures. The financial information relating to the Arena Group and HIIG contained in the MD&A is unaudited and has been derived from the financial statements of the related entities. Readers are cautioned that the HIIG financial information and certain Arena Group financial information, including any non-GAAP measures contained therein, has not been reconciled to IFRS and so may not be comparable to the financial information of issuers that present their financial information in accordance with IFRS.

About Westaim

Westaim is a Canadian investment company specializing in providing long-term capital to businesses operating primarily within the global financial services industry. The Company invests, directly and indirectly, through acquisitions, joint ventures and other arrangements, with the objective of providing its shareholders with capital appreciation and real wealth preservation. Westaim’s strategy is to pursue investment opportunities with a focus towards the financial services industry and grow shareholder value over the long term. Westaim’s investments include significant interests in HIIG and the Arena Group. HIIG, the HIIG Partnership, Arena, the Arena Group, Arena FINCOs, Arena Finance II, LLC, and Arena Investors are defined in the notes to Westaim’s unaudited consolidated financial statements for the three and nine months ended September 30, 2020 and 2019 and the MD&A. Westaim’s Common Shares are listed on the TSX Venture Exchange under the trading symbol WED.

For more information, contact:

J. Cameron MacDonald, President and Chief Executive Officer or

Robert T. Kittel, Chief Operating Officer

The Westaim Corporation

[email protected]

(416)969-3333

The Westaim Corporation

Financial Highlights

(millions of U.S. dollars except share and per share data)

Highlights

 

Three months ended September 30

 

Nine months ended September 30

(millions except share and per share data)

 

2020

 

2019

 

2020

 

2019

 

 

 

 

 

 

 

 

 

Revenue and net change in unrealized value of investments

 

$

4.0

 

 

$

4.8

 

 

$

(16.1

)

 

$

29.3

 

Net expenses

 

 

(3.4

)

 

 

(1.1

)

 

 

(3.8

)

 

 

(7.7

)

Income tax expense

 

 

 

 

 

 

 

(0.1

)

 

 

 

Profit (loss) and comprehensive income (loss)

 

$

0.6

 

 

$

3.7

 

 

$

(20.0

)

 

$

21.6

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share – basic

 

$

 

 

$

0.03

 

 

$

(0.14

)

 

$

0.15

 

Earnings (loss) per share – diluted

 

$

 

 

$

0.03

 

 

$

(0.14

)

 

$

0.15

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2020

 

December 31, 2019

Assets

 

 

 

 

Cash

 

$

8.3

 

$

22.2

Income tax receivable

 

 

0.5

 

 

0.4

Other assets

 

 

1.5

 

 

2.3

Investments

 

 

377.3

 

 

385.8

 

 

$

387.6

 

$

410.7

 

 

 

 

 

Liabilities

 

 

 

 

Accounts payable and accrued liabilities

 

$

9.4

 

$

10.7

Income tax payable

 

 

0.3

 

 

0.4

Preferred securities

 

 

37.6

 

 

38.5

Derivative warrant liability

 

 

0.8

 

 

1.9

Site restoration provision

 

 

4.1

 

 

4.1

Deferred tax liability

 

 

0.4

 

 

0.3

 

 

 

52.6

 

 

55.9

 

 

 

 

 

Shareholders’ equity

 

 

335.0

 

 

354.8

Total liabilities and shareholders’ equity

 

$

387.6

 

$

410.7

 

 

 

 

 

 

 

 

 

 

Number of common shares outstanding1

 

 

143,186,718

 

 

143,186,718

Book value per share – in US$2

 

$

2.33

 

$

2.48

Book value per share – in C$2

 

$

3.10

 

$

3.22

 

 

 

 

 

 1  

At September 30, 2020 and December 31, 2019, an aggregate of 3,034,261 RSUs, 10,428,337 stock options and 14,285,715 warrants were also outstanding. Details regarding these RSUs, stock options and warrants are disclosed in the Company’s public filings including its quarterly and annual financial statements which are available under the Company’s profile on SEDAR at www.sedar.com.

 2  

Non-GAAP measure. See Section 15, Non-GAAP Measures of the MD&A for a reconciliation to the most comparable IFRS figures.

   

Period end exchange rates: 1.33125 at September 30, 2020 and 1.29865 at December 31, 2019.

Except for statements of historical fact contained herein, information in this press release may constitute “forward-looking information” within the meaning of Canadian securities laws. Other than statements of historical fact, all statements that involve various known and unknown risks, uncertainties and other factors are “forward-looking statements”. There can be no assurance that such statements will prove accurate. Results and future events could differ materially from those anticipated in such statements. Readers of this press release are cautioned not to place undue reliance on these “forward-looking statements”. Except as otherwise required by applicable law, Westaim expressly disclaims any intention or obligation to update publicly any forward-looking information, whether as a result of new information, future events or otherwise. The information provided herein does not constitute an offer or solicitation regarding any investment products offered by Arena Group.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The Westaim Corporation

[email protected]

(416)969-3333

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo
Logo

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2020

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2020

FRIEDBERG, Germany–(BUSINESS WIRE)–
voxeljet AG (NASDAQ: VJET) (the “Company”, or “voxeljet”), a leading provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, today announced consolidated financial results for the third quarter ended September 30, 2020.

Highlights – Third Quarter 2020 compared to the Third Quarter 2019

  • Total revenues for the third quarter increased 10.6% to kEUR 4,908 from kEUR 4,436
  • Gross profit margin increased to 32.7% from 19.5%
  • Systems revenues increased 64.2% to kEUR 2,686 from kEUR 1,636
  • Services revenues decreased 20.6% to kEUR 2,222 from kEUR 2,800
  • Lowered full year revenue guidance to between kEUR 20,700 and kEUR 22,700
  • Revenue for the fourth quarter of 2020 is expected to be in the range of kEUR 8,000 to kEUR 10,000.

Dr. Ingo Ederer, Chief Executive Officer of voxeljet, commented, “We have reached three significant milestones with VJET X and the new, large High Speed Sintering (“HSS”) 3D printer over the last months: first, we received the follow-up orders for three additional VJET X units. The order comes as part of a frame contract concluded in 2018 between us and our partners and a premium German car maker. Second, just recently, we received the pre-acceptance from the car maker and our partners for the first two units, which were installed in 2019. We expect to recognize revenue for the first batch of five VJET X units mid-2021. Third, in HSS, we have found a clever and self-adjusting solution to address the challenge of having a stable temperature across a large powder bed: we have filed an IP accordingly. First printing tests on the large HSS printer were successful and we are extremely excited about the new opportunities and markets we plan to address with it.”

Three Months Ended September 30, 2020 Results

Revenues for the third quarter of 2020 increased by 10.6% to kEUR 4,908 compared to kEUR 4,436 in the third quarter of 2019.

Revenues from our Systems segment, which focuses on the development, production and sale of 3D printers, increased 64.2% to kEUR 2,686 in the third quarter of 2020 from kEUR 1,636 in last year’s third quarter. The Company sold two used and refurbished 3D printers in the third quarter of 2020 compared to three new 3D printers in last year’s third quarter. Revenue from the sale of 3D printers significantly increased due to the product mix, as we sold larger scale platforms in the third quarter of 2020 as opposed to smaller platforms in the comparative period. Systems revenues also include all Systems-related revenues from consumables, spare parts and maintenance. Those Systems-related revenues increased in the third quarter year over year, which reflects the higher installed base of 3D printers in the market and the associated growth in aftersales activities, although we were not able to achieve the targeted numbers. Revenues from the sale of 3D printers as well as Systems-related revenues were still impacted by the economic slow-down due to the ongoing global pandemic of COVID-19 disease (“the COVID-19 situation”). We were not able to perform all of the installations of 3D printers, which were scheduled for the third quarter of 2020 due to reimpositions of travel restrictions and shutdowns with the resurgence of COVID-19 cases in countries where our clients are located. As a consequence, we were not able to recognize revenue on those transactions. The same issues limited our ability to perform service and maintenance visits world wide, which also adversely affected our opportunities to recognize revenue. As many of our clients have reduced their production activities, the demand for consumables as well as spare and wear parts was on a lower level than expected, nevertheless we saw a recovery of demand compared to the prior two quarters in 2020. Systems revenues represented 54.7% of total revenues in the third quarter of 2020 compared to 36.9% in last year’s third quarter.

Revenues from our Services segment, which focuses on the printing of on-demand parts for our customers, decreased 20.6% to kEUR 2,222 in the third quarter of 2020 from kEUR 2,800 in the comparative period of 2019. This was mainly due to lower revenue contributions from our subsidiary voxeljet America Inc. (“voxeljet America”) related to the COVID-19 situation leading to a significant decrease in demand from our clients in North America. In addition, revenues from our subsidiary voxeljet UK Ltd. (“voxeljet UK”) significantly decreased. This was related to the close down of our service center in the United Kingdom in the fourth quarter of 2019 in the course of our restructuring, which started in the third quarter of 2019. For the German operation as well as for our subsidiary voxeljet China Co. Ltd. (“voxeljet China”), we saw a considerable market recovery in the third quarter of 2020 compared to the second quarter of 2020. Demand from our clients and associated revenues were approximately on the same level as last year’s third quarter.

Cost of sales were kEUR 3,301 for the third quarter of 2020 compared to kEUR 3,571 for the third quarter of 2019.

Gross profit and gross profit margin were kEUR 1,607 and 32.7%, respectively, in the third quarter of 2020 compared to kEUR 865 and 19.5% in the third quarter of 2019.

Gross profit for our Systems segment increased to kEUR 1,060 in the third quarter of 2020 from kEUR 357 in third quarter of 2019. Gross profit margin for this segment increased to 39.5% in the third quarter of 2020 compared to 21.8% in the third quarter of 2019. This was mainly due to higher gross profit and gross profit margin from the sale of 3D printers due to a more favorable product mix. But also gross profit and gross profit margin from Systems-related revenues slightly increased due to the product mix.

Gross profit for our Services segment slightly increased to kEUR 547 in the third quarter of 2020 compared to kEUR 508 in the third quarter of 2019. Gross profit margin for this segment significantly increased to 24.6% in the third quarter of 2020 from 18.1% in the third quarter of 2019. This was mainly due to neutral gross profit as well as gross profit margin contribution from voxeljet UK, as a result of the close down of our service center in the United Kingdom that began in the last year’s third quarter, accompanied by negative contributions. Further, gross profit and gross profit margin contribution from the German operation improved due to cost savings measures implemented as a consequence of the COVID-19 situation. Regarding voxeljet America, the decrease in revenues quarter over quarter led to a lower utilization of the American service center, resulting in significantly lower gross profit and gross profit margin contribution. Gross profit as well as gross profit margin contribution from voxeljet China slightly improved quarter over quarter.

Selling expenses were kEUR 1,295 for the third quarter of 2020 compared to kEUR 1,687 in the third quarter of 2019. Despite an increase in revenues, we recorded a decrease in selling expenses which was mainly due to lower selling expenses from voxeljet UK as a result of the successful restructuring, which started in the last year’s third quarter. In addition, we incurred lower expenses for travelling, trade fairs and exhibitions related to the COVID-19 situation and the associated global restrictions. Usually distributions expenses like shipping and packaging costs are a main driver of the selling expenses and can vary from quarter to quarter depending on quantity and types of products sold, as well as the destinations of where those goods are being delivered.

Administrative expenses were kEUR 1,477 for the third quarter of 2020 compared to kEUR 1,567 in the third quarter of 2019. The decrease was mainly due to significantly lower administrative expense from voxeljet UK as a result of the completed restructuring. This was partially offset by higher consulting fees related to the voluntary transfer of the listing of our American Depositary Shares (“ADSs”) from The New York Stock Exchange (the “NYSE”) to the NASDAQ Capital Market (“NASDAQ”) in August 2020, as previously disclosed in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”).

Research and development (“R&D”) expenses decreased to kEUR 1,482 in the third quarter of 2020 from kEUR 1,888 in the third quarter of 2019. The decrease of kEUR 406 was mainly due to lower personnel expenses as well as lower material consumption. Those expenses can vary from quarter to quarter and are usually driven by the different project types and phases.

Other operating expenses in the third quarter of 2020 were kEUR 590 compared to kEUR 36 in the prior year period. This was mainly due to higher losses from foreign currency transactions of kEUR 570 for the third quarter of 2020 compared to kEUR 22 for the third quarter of 2019.

Other operating income was kEUR 223 for the third quarter of 2020 compared to kEUR 787 in the third quarter of 2019. The decrease was mainly due to lower gains from foreign currency transactions, which decreased to kEUR 109 for the third quarter of 2020, compared to kEUR 642 in the last year’s third quarter.

The changes in foreign currency losses and gains were primarily driven by the valuation of the intercompany loans granted by the parent company to our UK and US subsidiaries.

Operating loss was kEUR 3,014 in the third quarter of 2020, compared to an operating loss of kEUR 3,526 in the comparative period in 2019. This was mainly related to the significant improvement in gross profit in the third quarter of 2020 compared to the third quarter of 2019. In addition, operating expenses within all functions decreased quarter over quarter, especially within the sales and marketing and R&D functions. This was partially offset by a negative net impact from other operating expenses and other operating income amounting to kEUR 367 for the third quarter of 2020 compared to a positive net impact amounting to kEUR 751 for the third quarter of 2019.

Financial result was negative kEUR 928 in the third quarter of 2020, compared to a financial result of negative kEUR 141 in the comparative period in 2019. This was mainly related to higher finance expenses related to the revaluation of derivative financial instruments, amounting to kEUR 481, compared to a finance income of kEUR 74 in the third quarter of 2019. The derivative financial instruments are revalued on each balance sheet date, with changes in the fair value between reporting periods recorded within financial result of the consolidated statements of comprehensive loss. An increase in our share price results in a finance expense, while a decrease leads to a finance income. Interest expense included interest from long term debt with other financial institutions which amounted to kEUR 486 for the third quarter of 2020, compared to kEUR 254 in the comparative period in 2019. The increase is mainly related to the draw down of the second tranche of the loan granted by the European Investment Bank (“EIB”) under the Finance Contract in June 2020 amounting to kEUR 5,000. This second tranche includes both, a Performance Participation Interest (PPI), accounted for separately as derivative financial instruments (included within the revaluation mentioned above) and also a fixed interest, which is recorded as interest from long term debt.

Net loss for the third quarter of 2020 was kEUR 4,035 or EUR 0.82 per share, as compared to net loss of kEUR 3,735, or EUR 0.76 per share, in the third quarter of 2019.

Effective August 14, 2020, we changed the ratio of our American Depositary Shares (“ADSs”) to ordinary shares from each ADS representing one-fifth (1/5) of one ordinary share (5:1) to each ADS representing one ordinary share (1:1). Based on a conversion rate of one ADSs per ordinary share, net loss was at EUR 0.82 per ADS for the third quarter of 2020, compared to a net loss of EUR 0.15 per ADS for the third quarter of 2019, based on a conversion rate of five ADSs per ordinary share. Earnings per share is computed by dividing net income attributable to stockholders of the parent by the weighted-average number of ordinary shares outstanding during the periods. Earnings per ADS is calculated by dividing the above earnings per share by one (before August 14, 2020: five) as each ordinary share represents one (before August 14, 2020: five) ADS(s).

Nine Months Ended September 30, 2020 Results

Revenues for the nine months ended September 30, 2020 decreased by 15.6% to kEUR 12,708 compared to kEUR 15,051 in the prior year period.

Systems revenues were kEUR 5,862 for the first nine months of 2020 compared to kEUR 6,180 for the same period last year. The Company sold two new and three used and refurbished 3D printers during the first nine months of 2020, compared to seven new and one used and refurbished 3D printer in the prior year period. Although, the Company sold a smaller number of units, revenue from the sale of 3D printers slightly increased due to the product mix, as we sold larger scale platforms in the first nine months of 2020 as opposed to smaller platforms in the comparative period in 2019. Nevertheless, the COVID-19 situation, including resurgence of COVID-19 cases and the reimpositions of travel restrictions or even shutdowns in countries where our clients are located, prohibited us from performing all of the scheduled installations of 3D printers. Therefore, we were not able to recognize revenue on those transactions. Systems revenues also include revenues from consumables, spare parts and maintenance. Also, those Systems-related revenues were significantly impacted by the COVID-19 situation, as the performance of service visits was limited in many regions of the world, which made it impossible to fulfill our maintenance schedule. Further, we experienced lower demand for consumables and spare parts in the first nine months of 2020, as our clients have reduced their production activities, especially in the second quarter of 2020. All those matters led to a decrease in Systems-related revenues. In the third quarter of 2020, demand for consumables and spare parts substantially recovered compared to the prior two quarters in 2020. Systems revenues represented 46.1% of total revenue for the nine months ended September 30, 2020 compared to 41.1% for the same period in the prior year.

Services revenues were kEUR 6,846 for the nine months ended September 30, 2020 compared to kEUR 8,871 for the same period last year. This decrease of 22.8% was mainly due to significantly lower revenue contributions from our subsidiary voxeljet America Inc. (“voxeljet America”), related to the COVID-19 situation, leading to a significant decrease in demand from our clients. We incurred similar impacts for the German service center, where revenues also decreased, although not as strong as in the US. Revenue contribution from our subsidiary voxeljet UK Ltd. (“voxeljet UK”) significantly decreased. This was related to the close down of our service center in the United Kingdom in the fourth quarter of 2019 in the course of our restructuring, which started in the third quarter of 2019. Also, revenues from our subsidiary voxeljet China Co. Ltd. (“voxeljet China”) were impacted by the economic slow-down due to COVID-19 and therefore slightly decreased.

Cost of sales for the nine months ended September 30, 2020 were kEUR 8,931, a decrease of kEUR 1,816, over cost of sales of kEUR 10,747 for the same period in 2019.

Gross profit and gross profit margin for the nine months ended September 30, 2020 were kEUR 3,777 and 29.7%, respectively, compared to kEUR 4,304 and 28.6% in the prior year period.

Gross profit for our Systems segment increased to kEUR 2,040 for the nine months ended September 30, 2020 from kEUR 1,717 in the same period in 2019. Also, gross profit margin for this segment improved to 34.8% compared to 27.8% for the prior year period. This was related to a more favorable product mix, especially regarding Systems-related revenues, but also regarding revenues from the sale of 3D printers, as larger scale platforms usually provide higher gross profit (margins) compared to smaller platforms.

Gross profit for our Services segment decreased to kEUR 1,737 for the nine months ended September 30, 2020 from kEUR 2,587 in the same period of 2019. The gross profit margin for this segment decreased to 25.4% for the first nine months of 2020 from 29.2% in the same period in 2019. This was mainly related to significantly lower gross profit as well as gross profit margin contribution from our American service center, as a result of lower utilization in line with the decrease in revenues. Gross profit as well as gross profit margin contribution from our German service center slightly improved year over year in spite of the decline in revenues, due to cost savings measures implemented as a consequence of the COVID-19 situation. Gross profit and gross profit margin contribution from voxeljet China remained almost unchanged.

Selling expenses were kEUR 4,136 for the nine months ended September 30, 2020 compared to kEUR 5,125 in the same period in 2019. The year over year decrease is mainly due to lower distribution expenses corresponding to the decrease in revenues. Shipping and packaging expenses as a main driver of the selling expenses could vary from quarter to quarter depending on quantity and types of products, as well as the destinations where those goods are being delivered. Further, selling expenses from voxeljet UK significantly decreased as a result of the successful restructuring, which started in the last year’s third quarter. In addition, we incurred lower expenses for travelling, trade fairs and exhibitions related to the COVID-19 situation and the associated global restrictions.

Administrative expenses slightly increased by kEUR 103 to kEUR 4,694 for the first nine months of 2020 from kEUR 4,591 in the prior year’s period. The increase was mainly due to higher unexpected advisor fees in the second quarter of 2020, mainly related to the Audit Committee Investigation as previously disclosed in the Company’s SEC filings. This was largely offset by significantly lower administrative expense from voxeljet UK as a result of the completed restructuring.

R&D expenses decreased to kEUR 4,737 for the nine months ended September 30, 2020 from kEUR 5,295 in the same period in 2019, a decrease of kEUR 558. The decrease was mainly due to lower personnel expenses as well as lower material consumption. Those expenses can vary from quarter to quarter and are usually driven by the different project types and phases.

Other operating expenses for the nine months ended September 30, 2020 were kEUR 1,958 compared to kEUR 422 in the prior year period. This was mainly due to higher losses from foreign currency transactions amounting to kEUR 1,859 for the nine months ended September 30, 2020 compared to kEUR 395 in the prior year’s period.

Other operating income was kEUR 1,258 for the nine months ended September 30, 2020 compared to kEUR 1,468 in the prior year period. The decrease was mainly due to lower gains from foreign exchange transactions amounting to kEUR 489 for the nine months ended September 30, 2020 compared to kEUR 1,088 for the comparative period in 2019. This was partially offset by a government grant received by voxeljet America in April 2020 from the United States Small Business Administration (“SBA”) under the COVID-19 funding program amounting to kEUR 295. The full amount was recognized in profit and loss, in the second quarter of 2020, as the related costs for which the grant is intended to compensate, occurred in this period and we assume that we comply with the conditions of the funding. The assessment of SBA whether we are in compliance with the conditions, has not been performed yet.

The changes in foreign currency losses and gains were primarily driven by the valuation of the intercompany loans granted by the parent company to our UK and US subsidiaries.

Operating loss was kEUR 10,490 in the nine months ended September 30, 2020 compared to an operating loss of kEUR 9,661 in the comparative period in 2019. This was primarily driven by the net impact from other operating expenses and other operating income amounted to kEUR 700 negative for the nine months ended September 30, 2020, compared to kEUR 1,046 positive for the nine months ended September 30, 2019. In addition, gross profit decreased significantly, while administrative expenses slightly increased compared to the nine months ended September 30, 2019. This was partially offset by lower operating expenses within the functions sales and marketing and R&D for the nine months ended September 30, 2020 compared to the last year’s same period.

Financial result was negative kEUR 1,119 for the nine months ended September 30, 2020, compared to a financial result of negative kEUR 487 in the comparative period in 2019. This was mainly due to higher interest expense for long-term debt which amounted to kEUR 1,094 in the nine months ended September 30, 2020, compared to kEUR 745 for the nine months ended September 30, 2019. This increase is mainly due to the fixed interest related to the second tranche of the loan granted by the European Investment Bank (“EIB”) under the Finance Contract in June 2020 amounting to kEUR 5,000, which has been drawn down in June 2020. Finance income and expense related to the revaluation of derivative financial instruments amounted to kEUR 486 and kEUR 394, respectively for the nine months ended September 2020, compared to a finance income and expense of kEUR 133 and kEUR 0, respectively in the last year’s same period.

Net loss for the nine months ended September 30, 2020 was kEUR 11,759, or EUR 2.41 per share, as compared to net loss of kEUR 10,271, or EUR 2.09 per share in the prior year period.

Effective August 14, 2020, we changed the ratio of our American Depositary Shares (“ADSs”) to ordinary shares from each ADS representing one-fifth (1/5) of one ordinary share (5:1) to each ADS representing one ordinary share (1:1). Based on a conversion rate of one ADSs per ordinary share, net loss was EUR 2.41 per ADS for the nine months ended September 30, 2020, compared to net loss of EUR 0.42 per ADS in the prior year period, based on a conversion rate of five ADSs per ordinary share.

Business Outlook

Our revenue guidance for the fourth quarter of 2020 is expected to be in the range of kEUR 8,000 to kEUR 10,000. We lowered full year revenue guidance to between kEUR 20,700 and kEUR 22,700 from kEUR 26,000 to kEUR 30,000, mainly due to reimpositions of travel restrictions and closings in countries where our clients are located which caused further delays in scheduled 3D printer installations.

For gross profit margin, we expect gross profit margin to be above 40% for the fourth quarter of 2020 rather than for the full year and adjusted EBITDA to be neutral-to-positive also for the fourth quarter of 2020 rather than for the second half of the year ending December 31, 2020. Those changes are a result of lower than expected gross profit for the third quarter of 2020. For full year guidance, we expect:

– Full year revenue is expected to be in the range of kEUR 20,700 to kEUR 22,700

– Gross profit margin for the fourth quarter of 2020 is expected to be above 40%

– Operating expenses for the full year are expected as follows: selling and administrative expenses are expected to be in the range of kEUR 13,000 to kEUR 13,250 and R&D expenses are projected to be between approximately kEUR 5,750 and kEUR 6,250. Depreciation and amortization expense is expected to be between kEUR 3,500 and kEUR 3,750.

– Adjusted EBITDA for the fourth quarter of 2020 is expected to be neutral-to-positive. Adjusted EBITDA is defined as net income (loss), as calculated under IFRS accounting principles before interest (income) expense, provision (benefit) for income taxes, depreciation and amortization, and excluding other operating (income) expense resulting from foreign exchange gains or losses on the intercompany loans granted to the subsidiaries.

– Capital expenditures are projected to be in the range of kEUR 500 to kEUR 1,000, which primarily includes ongoing investments in our global subsidiaries.

Our total backlog of 3D printer orders at September 30, 2020 was kEUR 9,445, which represents eleven 3D printers. This compares to a backlog of kEUR 2,792 representing three 3D printers, at December 31, 2019. As production and delivery of our printers is generally characterized by lead times ranging between three to nine months, the conversion rate of order backlog into revenue is dependent on the equipping process for the respective 3D printer, as well as the timing of customers’ requested deliveries.

At September 30, 2020, we had cash and cash equivalents of kEUR 5,975 and held kEUR 2,922 of investments in bond funds, thereof kEUR 2,000 restricted, which are included in current financial assets on our consolidated statements of financial position.

Webcast and Conference Call Details

The Company will host a conference call and webcast to review the results for the third quarter 2020 on Friday, November 13, 2020 at 8:30 a.m. Eastern Time. Participants from voxeljet will include its Chief Executive Officer, Dr. Ingo Ederer, and its Chief Financial Officer, Rudolf Franz, who will provide a general business update and respond to investor questions.

Interested parties may access the live audio broadcast by dialing 1-877-705-6003 in the United States/Canada, or 1-201-493-6725 for international, Conference Title “voxeljet AG Third Quarter 2020 Financial Results Conference Call”. Investors are requested to access the call at least five minutes before the scheduled start time in order to complete a brief registration. An audio replay will be available approximately two hours after the completion of the call at 1-844-512-2921 or 1-412-317-6671, Replay Conference ID number 13712044. The recording will be available for replay through November 20, 2020.

A live webcast of the call will also be available on the investor relations section of the Company’s website. Please go to the website https://event.on24.com/wcc/r/2628507/D88FE2EA4FC838A12B6DE062756F809A at least fifteen minutes prior to the start of the call to register, download and install any necessary audio software. A replay will also be available as a webcast on the investor relations section of the Company’s website.

Non-IFRS Measure

Management regularly uses both IFRS and non-IFRS results and expectations internally to assess its overall performance of the business, making operating decisions, and forecasting and planning for future periods. Management believes that Adjusted EBITDA is a useful financial measure to the Company’s investors as it helps investors better understand and evaluate the projections our management board provides. The Company’s calculation of Adjusted EBITDA may not be comparable to similarly titled financial measures reported by other peer companies. Adjusted EBITDA should not be considered as a substitute to financial measures prepared in accordance with IFRS.

The Company uses Adjusted EBITDA as a supplemental financial measure of its financial performance. Adjusted EBITDA is defined as net income (loss), as calculated under IFRS accounting principles, interest (income) expense, provision (benefit) for income taxes, depreciation and amortization, and excluding other (income) expense resulting from foreign exchange gains or losses on the intercompany loans granted to the subsidiaries. Management believes Adjusted EBITDA to be an important financial measure because it excludes the effects of fluctuating foreign exchange gains or losses on the intercompany loans granted to its subsidiaries. We are unable to reasonably estimate the potential full-year financial impact of foreign currency translation because of volatility in foreign exchange rates. Therefore, we are unable to provide a reconciliation to our forward-looking guidance for non-GAAP Adjusted EBITDA without unreasonable effort as certain information necessary to calculate such measure on an IFRS basis is unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts by the Company.

Exchange rate

This press release contains translations of certain U.S. dollar amounts into euros at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from U.S. dollars to euros in this press release were made at a rate of USD 1.1723 to EUR 1.00, the noon buying rate of the Federal Reserve Bank of New York for the Euro on September 30, 2020.

About voxeljet

voxeljet is a leading provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers. The Company’s 3D printers employ a powder binding, additive manufacturing technology to produce parts using various material sets, which consist of particulate materials and proprietary chemical binding agents. The Company provides its 3D printers and on-demand parts services to industrial and commercial customers serving the automotive, aerospace, film and entertainment, art and architecture, engineering and consumer product end markets. For more information, visit http://www.voxeljet.de/en/.

Cautionary Statement on Forward-Looking Statements

This press release contains forward-looking statements concerning our business, operations and financial performance. Any statements that are not of historical facts may be deemed to be forward-looking statements. You can identify these forward-looking statements by words such as ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘projects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘aims,’’ or other similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements include statements regarding our intentions, beliefs, assumptions, projections, outlook, analyses or current expectations concerning, among other things, our results of operations, financial condition, business outlook, the industry in which we operate and the trends that may affect the industry or us. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance. All of our forward-looking statements are subject to known and unknown risks, uncertainties and other factors that are in some cases beyond our control and that may cause our actual results to differ materially from our expectations, including those risks identified under the caption “Risk Factors” in the Company’s Annual Report on Form 20-F and in other reports the Company files with the U.S. Securities and Exchange Commission, as well as the risk that our revenues may fall short of the guidance we have provided in this press release. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this press release whether as a result of new information, future events or otherwise.

voxeljet AG

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (UNAUDITED)

 

 

 

 

 

 

 

 

 

Notes

 

9/30/2020

 

12/31/2019 (1) (2)

 

 

 

 

(€ in thousands)

 

 

 

 

 

 

 

Current assets

 

 

 

29,182

 

 

31,513

 

Cash and cash equivalents

 

7

 

5,975

 

 

4,368

 

Financial assets

 

7

 

2,922

 

 

7,408

 

Trade receivables

 

7

 

4,630

 

 

5,915

 

Inventories

 

4

 

13,999

 

 

12,459

 

Income tax receivables

 

 

 

30

 

 

39

 

Other assets

 

 

 

1,626

 

 

1,324

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

28,952

 

 

31,052

 

Financial assets (2)

 

7

 

2,765

 

 

2,279

 

Intangible assets

 

 

 

1,199

 

 

1,356

 

Property, plant and equipment

 

5

 

24,919

 

 

27,343

 

Investments in joint venture

 

 

 

27

 

 

30

 

Other assets

 

 

 

42

 

 

44

 

 

 

 

 

 

 

 

Total assets

 

 

 

58,134

 

 

62,565

 

 

 

 

 

 

 

 

 

 

 

Notes

 

9/30/2020

 

12/31/2019 (1) (2)

 

 

 

 

 

 

 

Current liabilities

 

 

 

9,093

 

 

18,855

 

Trade payables

 

7

 

2,095

 

 

2,797

 

Contract liabilities

 

 

 

4,782

 

 

2,623

 

Financial liabilities

 

7

 

1,021

 

 

11,290

 

Other liabilities and provisions

 

6

 

1,195

 

 

2,145

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

25,878

 

 

10,192

 

Deferred tax liabilities (2)

 

 

 

331

 

 

142

 

Financial liabilities (2)

 

7

 

25,542

 

 

9,866

 

Other liabilities and provisions

 

6

 

5

 

 

184

 

 

 

 

 

 

 

 

Equity

 

 

 

23,163

 

 

33,518

 

Subscribed capital

 

 

 

4,836

 

 

4,836

 

Capital reserves

 

 

 

88,580

 

 

88,077

 

Accumulated deficit (1) (2)

 

 

 

(71,761

)

 

(60,124

)

Accumulated other comprehensive income (1)

 

 

 

1,643

 

 

742

 

Equity attributable to the owners of the company

 

 

 

23,298

 

 

33,531

 

Non controlling interest

 

 

 

(135

)

 

(13

)

Total equity and liabilities

 

 

 

58,134

 

 

62,565

 

See accompanying notes to unaudited condensed consolidated interim financial statements.

(1)Comparative figures for the year ended December 31, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the year ended December 31, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

voxeljet AG

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30,

 

Nine months ended September 30,

 

 

Notes

 

2020

 

2019 (1) (2)

 

2020

 

2019 (1) (2)

 

 

 

 

(€ in thousands except share and share data)

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

9, 10

 

4,908

 

 

4,436

 

 

12,708

 

 

15,051

 

Cost of sales

 

 

 

(3,301

)

 

(3,571

)

 

(8,931

)

 

(10,747

)

Gross profit

 

9

 

1,607

 

 

865

 

 

3,777

 

 

4,304

 

Selling expenses

 

 

 

(1,295

)

 

(1,687

)

 

(4,136

)

 

(5,125

)

Administrative expenses

 

 

 

(1,477

)

 

(1,567

)

 

(4,694

)

 

(4,591

)

Research and development expenses

 

 

 

(1,482

)

 

(1,888

)

 

(4,737

)

 

(5,295

)

Other operating expenses

 

 

 

(590

)

 

(36

)

 

(1,958

)

 

(422

)

Other operating income

 

 

 

223

 

 

787

 

 

1,258

 

 

1,468

 

Thereof income (expense) from changes in impairment allowance included in other operating income (expense)

 

 

 

41

 

 

(129

)

 

26

 

 

23

 

Operating loss

 

 

 

(3,014

)

 

(3,526

)

 

(10,490

)

 

(9,661

)

Finance expense (1) (2)

 

8

 

(1,005

)

 

(325

)

 

(1,692

)

 

(934

)

Finance income (1) (2)

 

8

 

77

 

 

184

 

 

573

 

 

447

 

Financial result

 

8

 

(928

)

 

(141

)

 

(1,119

)

 

(487

)

Loss before income taxes

 

 

 

(3,942

)

 

(3,667

)

 

(11,609

)

 

(10,148

)

Income tax expense (2)

 

 

 

(93

)

 

(68

)

 

(150

)

 

(123

)

Net loss

 

 

 

(4,035

)

 

(3,735

)

 

(11,759

)

 

(10,271

)

Other comprehensive income (loss) that may be reclassified subsequently to profit or loss (1)

 

 

 

89

 

 

(209

)

 

901

 

 

(193

)

Total comprehensive loss

 

 

 

(3,946

)

 

(3,944

)

 

(10,858

)

 

(10,464

)

 

 

 

 

 

 

 

 

 

 

 

Loss attributable to:

 

 

 

 

 

 

 

 

 

 

Owners of the Company

 

 

 

(3,955

)

 

(3,668

)

 

(11,637

)

 

(10,105

)

Non-controlling interests

 

 

 

(80

)

 

(67

)

 

(122

)

 

(166

)

 

 

 

 

(4,035

)

 

(3,735

)

 

(11,759

)

 

(10,271

)

 

 

 

 

 

 

 

 

 

 

 

Total comprehensive loss attributable to:

 

 

 

 

 

 

 

 

 

 

Owners of the Company

 

 

 

(3,866

)

 

(3,877

)

 

(10,736

)

 

(10,298

)

Non-controlling interests

 

 

 

(80

)

 

(67

)

 

(122

)

 

(166

)

 

 

 

 

(3,946

)

 

(3,944

)

 

(10,858

)

 

(10,464

)

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of ordinary shares outstanding

 

 

 

4,836,000

 

 

4,836,000

 

 

4,836,000

 

 

4,836,000

 

Loss per share – basic/ diluted (EUR)

 

 

 

(0.82

)

 

(0.76

)

 

(2.41

)

 

(2.09

)

See accompanying notes to unaudited condensed consolidated interim financial statements.

(1)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

voxeljet AG

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to the owners of the company

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

other

 

 

 

 

 

 

 

 

Subscribed

 

Capital

 

Accumulated

 

comprehensive

 

 

 

Non-controlling

 

 

(€ in thousands)

 

capital

 

reserves

 

deficit

 

gain (loss)

 

Total

 

interests

 

Total equity

Balance at December 31, 2018 (1) (2) (3)

 

4,836

 

86,803

 

(46,410

)

 

1,320

 

 

46,549

 

 

35

 

 

46,584

 

Loss for the period (1) (2)

 

 

 

(10,105

)

 

 

 

(10,105

)

 

(166

)

 

(10,271

)

Foreign currency translations

 

 

 

 

 

(193

)

 

(193

)

 

 

 

(193

)

Equity-settled share-based payment

 

 

501

 

 

 

 

 

501

 

 

 

 

501

 

Share-based payment transaction with the non-controlling shareholder of a subsidiary

 

 

604

 

 

 

 

 

604

 

 

216

 

 

820

 

Balance at September 30, 2019 (1) (2)

 

4,836

 

87,908

 

(56,515

)

 

1,127

 

 

37,356

 

 

85

 

 

37,441

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to the owners of the company

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

other

 

 

 

 

 

 

 

 

Subscribed

 

Capital

 

Accumulated

 

comprehensive

 

 

 

Non-controlling

 

 

(€ in thousands)

 

capital

 

reserves

 

deficit

 

gain (loss)

 

Total

 

interests

 

Total equity

Balance at December 31, 2019 (1) (2)

 

4,836

 

88,077

 

(60,124

)

 

742

 

33,531

 

 

(13

)

 

33,518

 

Loss for the period

 

 

 

(11,637

)

 

 

(11,637

)

 

(122

)

 

(11,759

)

Foreign currency translations

 

 

 

 

 

901

 

901

 

 

 

 

901

 

Equity-settled share-based payment

 

 

503

 

 

 

 

503

 

 

 

 

503

 

Balance at September 30, 2020

 

4,836

 

88,580

 

(71,761

)

 

1,643

 

23,298

 

 

(135

)

 

23,163

 

See accompanying notes to unaudited condensed consolidated interim financial statements.

(1)Comparative figures for the year ended December 31, 2018, the nine months ended September 30, 2019 and year ended December 31, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the year ended December 31, 2018, the nine months ended September 30, 2019 and year ended December 31, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

(3)The Company has initially applied IFRS 16 as of January 1, 2019, using the modified retrospective approach. Under this approach, comparative information is not restated and the cumulative effect of initially applying IFRS 16 is recognized in retained earnings at the date of initial application. For further information, see Form 20-F filed with the SEC on May 7, 2020, Part III, Item 18. Financial Statements, Note 3 of the consolidated financial statements.

voxeljet AG

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

 

 

 

 

 

 

Nine months ended September 30,

 

 

2020

 

2019 (1) (2)

 

 

(€ in thousands)

 

 

 

 

 

Cash Flow from operating activities

 

 

 

 

 

 

 

 

 

Loss for the period (1) (2)

 

(11,759

)

 

(10,271

)

 

 

 

 

 

Depreciation and amortization

 

2,657

 

 

3,200

 

Foreign currency exchange differences on loans to subsidiaries

 

1,217

 

 

(700

)

Changes in financial assets due to fair value valuation

 

73

 

 

(162

)

Share-based compensation expense

 

503

 

 

501

 

Change in impairment of trade receivables

 

(26

)

 

(23

)

Non-cash expense on financial liabilities

 

1,027

 

 

653

 

Change in fair value of derivative equity forward

 

(92

)

 

(132

)

Change in inventory allowance

 

(1

)

 

(21

)

Interest paid

 

199

 

 

254

 

Interest received

 

(86

)

 

(86

)

Loss on disposal of fixed assets

 

22

 

 

309

 

Other

 

209

 

 

107

 

 

 

 

 

 

Change in working capital

 

2

 

 

528

 

Trade and other receivables, inventories and current assets

 

(886

)

 

75

 

Trade payables

 

(642

)

 

(687

)

Other liabilities, contract liabilities and provisions

 

1,059

 

 

1,176

 

Change in restricted cash

 

463

 

 

 

Income tax payable/receivables

 

8

 

 

(36

)

Net cash used in operating activities

 

(6,055

)

 

(5,843

)

 

 

 

 

 

Cash Flow from investing activities

 

 

 

 

 

 

 

 

 

Payments to acquire property, plant and equipment and intangible assets

 

(182

)

 

(1,133

)

Proceeds from disposal of financial assets

 

4,962

 

 

7,973

 

Payments to acquire financial assets

 

(994

)

 

(1,251

)

Interest received

 

86

 

 

86

 

Others

 

 

 

5

 

Net cash from investing activities

 

3,872

 

 

5,680

 

 

 

 

 

 

Cash Flow from financing activities

 

 

 

 

 

 

 

 

 

Repayment of lease liabilities

 

(332

)

 

(158

)

Repayment of long-term debt

 

(664

)

 

(846

)

Proceeds from issuance of long-term debt

 

5,000

 

 

500

 

Interest paid

 

(199

)

 

(254

)

Net cash used in financing activities

 

3,805

 

 

(758

)

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

1,622

 

 

(921

)

 

 

 

 

 

Cash and cash equivalents at beginning of period

 

4,368

 

 

7,402

 

Changes to cash and cash equivalents due to foreign exchanges rates

 

(15

)

 

92

 

Cash and cash equivalents at end of period

 

5,975

 

 

6,573

 

See accompanying notes to unaudited condensed consolidated interim financial statements.

(1)Comparative figures for the nine months ended September 30, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the nine months ended September 30, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

voxeljet AG

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. Preparation of financial statements

Our condensed consolidated interim financial statements include the accounts of voxeljet AG and its wholly-owned subsidiaries voxeljet America Inc., voxeljet UK Ltd. and voxeljet India Pvt. Ltd., as well as voxeljet China Co. Ltd., which are collectively referred to herein as the ‘Group’ or the ‘Company’, which is listed on the NASDAQ Capital Market (“NASDAQ”).

As previously disclosed, on August 18, 2020, the Company announced that it would voluntarily transfer the listing of its American Depositary Shares (“ADSs”) from the New York Stock Exchange (the “NYSE”) to the NASDAQ, effective August 28, 2020, after market close. voxeljet’s ADSs began trading as a NASDAQ-listed security at market open on August 31, 2020, and have continued to be listed under the ticker symbol “VJET.”

As previously disclosed, on July 31, 2020, the Company announced that it would change the ratio of its American Depositary Shares (“ADSs”) to ordinary shares from each ADS representing one-fifth (1/5) of one ordinary share (5:1) to each ADS representing one ordinary share (1:1). For ADS holders, the ratio change had the same effect as a 1 for 5 reverse ADS split. The ratio change became effective on August 14, 2020 (the “Effective Date”). On the Effective Date, each ADS holder was required to exchange every five (5) ADSs then held for one (1) new ADS (e.g., if a holder of ADSs previously held 50 ADSs, following the ratio change on the Effective Date, such holder helds 10 ADSs). Citibank, N.A., as depositary bank, has arranged for the exchange of the current ADSs for the new ones. There was no change to voxeljet’s underlying ordinary shares.

Our condensed consolidated interim financial statements were prepared in compliance with all applicable measurement and presentation rules contained in International Financial Reporting Standards (‘IFRS’) as set forth by the International Accounting Standards Board (‘IASB’) and Interpretations of the IFRS Interpretations Committee (‘IFRIC’). The designation IFRS also includes all valid International Accounting Standards (‘IAS’); and the designation IFRIC also includes all valid interpretations of the Standing Interpretations Committee (‘SIC’). Specifically, these financial statements were prepared in accordance with the disclosure requirements and the measurement principles for interim financial reporting purposes specified by IAS 34. Our condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019. The results of operations for the three months ended September 30, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020.

The IASB issued a number of new IFRS standards which are required to be adopted in annual periods beginning after January 1, 2020.

 

 

 

Standard

Effective date

Descriptions

Others

01/2020

Amendments References to the Conceptual Framework in IFRS Standards 3

IFRS 3

01/2020

Amendment Definition of a business

IAS 1, IAS 8

01/2020

Amendment, Amendment Definition of material

IFRS 9, IAS 39, IFRS 7

01/2020

Amendments to IFRS 9, IAS 39 and IFRS 7 – Interest rate benchmark reform

IFRS 16

06/2020

COVID-19 related rent concessions amendment to IFRS 16

IFRS 17

01/2021

Insurance Contracts

IAS 1

01/2022

Classifications of Liabilities as Current or Non-Current (Amendment to IAS 1)

The adoption of standards effective 01/2020 did not have a material impact on the interim financial statements as of and for the three and nine months ended September 30, 2020. The Company has not yet conclusively determined what impact the new standards, amendments or interpretations effective 01/2021 or later will have on its financial statements, but does not expect they will have a significant impact.

The interim financial statements as of and for the three and nine months ended September 30, 2020 and 2019 were authorized for issue by the Management Board on November 12, 2020.

Going concern

The financial statements have been prepared on the basis of going concern which contemplates continuity of normal business activities and the realization of assets and settlement of liabilities in the ordinary course of business.

voxeljet has recognized continuous net losses during the nine months ended September 30, 2020, full year 2019, 2018 and 2017 amounting to kEUR 11,759, kEUR 13,978, kEUR 8,747 and kEUR 8,581, respectively. Additionally, voxeljet had negative cash flows from operating activities in the nine months ended September 30, 2020, full year 2019, 2018 and 2017 of kEUR 6,055, kEUR 6,819, kEUR 7,714 and kEUR 6,830, respectively, mainly due to continuous net losses.

Due to the global outbreak of a new strain of coronavirus, we have experienced and expect to continue to experience lower demand in both, our Systems and Services segment. Our clients have postponed and may continue to postpone larger investments and therefore, the demand for 3D printers may also decrease. In addition, the COVID-19 situation could cause further delays in installation of 3D printers at customers’ facilities, which could lead to postponed revenue recognition for those transactions. In the third quarter of 2020, we experienced a slight recovery of demand compared to the prior two quarters in 2020, but we are still not on the level before the global economic crisis as a consequence of COVID-19. Both a decrease in revenues as well as potential delays in the installations increase the risk and likelihood of lower cash inflows. Such risks have been evaluated by management and consequently have been considered in our liquidity forecast, which assumes our business plan is executed appropriately and sales track as expected. We update our liquidity forecast on an ongoing basis.

As we experience difficulty in generating sufficient cash flow to meet our obligations and sustain our operations, the COVID-19 situation raises material uncertainties that may cast substantial doubt about our ability to continue as a going concern. Further, material deviations from our forecasts could lead to a covenant breach in the future, which could result in an acceleration of our obligation to repay all amounts outstanding under those facilities.

Despite the ongoing losses, reduced cash flow and cash facilities, and the other negative financial conditions, management assumes that voxeljet will continue as a going concern, as the Company has been successful in drawing down kEUR 5,000 of the second tranche of the loan granted by the EIB under the Finance Contract in June 2020. This improved our liquidity significantly. Also, the financial covenants under the Finance Contract have been renegotiated to replace the Total Net Financial Debt to EBITDA ratio with a minimum cash/cash equivalents requirement. In addition, the restructuring of the voxeljet UK entity, which included consolidating 3D printing to serve all customers in Europe from the German service center has been finished. This helps to reduce overall costs and will lead to improved gross profit margins by realizing economies of scale in the German service center. Further, management initiated a restructuring program at the German entity during the fourth quarter of 2019. This program included the reduction of headcount mainly in the Systems segment in order to streamline the Company’s operations and optimize efficiency. This restructuring was successfully completed at the end of June 2020 and will provide further cost reductions.

Management is also taking steps to raise further funds which may include debt or equity financing. There can be no assurance that we will be able to raise further funds on terms favorable to us, if at all.

Based on our current liquidity and capital resources in combination with our current liquidity forecasts, as well as the implemented cost reduction program, management believes that the Company has the ability to meet its financial obligations for at least the next 12 months and therefore continues as a going concern. However, the matters described above give rise to material uncertainties that may cast substantial doubt about the Company’s ability to continue as a going concern.

Impairment test

Non-financial assets are tested for impairment if there are indicators that the carrying amounts may not be recoverable. The Company considers the COVID-19 situation as such an indicator. Therefore, voxeljet performed an impairment test for the non‑financial assets for the end of the reporting period. An impairment loss is recognized in the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is defined as the higher of an asset’s fair value less cost to sell and its value in use. As individual assets do not generate largely independent cash flows, impairment testing is performed at the cash generating unit level. An individual fixed asset within a CGU cannot be written down below fair value less cost incurred to sell the individual asset. The impairment test, which we performed, did not lead to any write downs.

Amendment and recalculation

a) Amendment of classification of short-term investments

In the first quarter of 2020, we amended our classification of short-term investments included in current financial assets. Before the amendment, those short-term investments have been classified in the category at fair value through OCI (FVOCI).

The new classification shall be the category at fair value through profit and loss (FVTPL). Accordingly, prior periods have been revised, which leads to movements between profit and loss and other comprehensive income as the changes in fair value are now presented within finance income or expense.

b) Recalculation of performance participation interest related to the Finance Contract with the EIB

In the first quarter of 2020, we recalculated the performance participation interest related to the Finance Contract with the EIB, due to a mistake in the calculation logic. Accordingly, prior periods have been revised, which leads to adjustments in non current financial assets, deferred tax liabilities as well as equity.

c) Impacts of amendment and recalculation

Due to the amendments and recalculations, which are described above, the opening balance as of January 1, 2019 of non current financial assets as well as deferred tax liabilities have increased by kEUR 151 and kEUR 43 respectively. The opening balance as of January 1, 2019 of accumulated deficit increased by kEUR 10, whereas the opening balance of accumulated other comprehensive gain increased by kEUR 119. As a result, the loss for the nine months ended September 2019 decreased by kEUR 346.

As of September 30, 2019, non current financial assets as well as deferred tax liabilities have increased by kEUR 370 and kEUR 104, respectively. For the period ending September 30, 2019 the balance of accumulated deficit decreased by kEUR 336, whereas the balance of accumulated other comprehensive gain decreased by kEUR 69.

As a result, the loss for the three months ended September 2019 was decreased by kEUR 178 whereas net changes in fair value of debt investments at FVOCI was reduced by kEUR 48. For the nine month ended September 2019 the loss was reduced by kEUR 346 whereas net changes in fair value of debt investments at FVOCI was reduced by kEUR 188.

As of December 31, 2019, non current financial assets as well as deferred tax liabilities have increased by kEUR 260 and kEUR 73, respectively. As of December 31, 2019 the balance of accumulated deficit decreased by kEUR 243 whereas the balance of accumulated other comprehensive gain was reduced by kEUR 56.

The Company has evaluated the effect of these amendments, both qualitatively and quantitatively, and concluded that the change did not have a material impact on, nor require amendment of, any previously filed financial statements. Affected financial statement line items for prior periods are appended with a footnote.

2. Summary of significant accounting policies

The principal accounting policies applied in the preparation of these interim financial statements are set out in the Company’s financial statements as of December 31, 2019, which can be found in its Annual Report on Form 20-F that was filed with the U.S. Securities and Exchange Commission. These policies have been applied to all financial periods presented.

Government grants

Government grants in connection with government assistance to help businesses to mitigate adverse impacts from the COVID-19 global pandemic are recognized in profit or loss on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate, provided that the entity complies with the conditions for the funding.

Short-term investments

In the first quarter of 2020, we amended our classification of short-term investments included in current financial assets. Before the amendment, those short-term investments have been classified in the category at fair value through OCI (FVOCI). For further information, see Note 1.

3. Share based payment arrangements

On April 7, 2017, voxeljet AG established a share option plan that entitles key management personnel and senior employees of voxeljet AG and its subsidiaries to purchase shares of the parent company.

Total options available under the share option plan are 372,000. On April 7, 2017 279,000 options (75%, Tranche 1) were granted. On April 12, 2018 93,000 options (25%, Tranche 2) were granted.

The vesting conditions include a service condition (the options vest after a period of four years of continued service from the respective grant date) and a market condition (the options may only be exercised if the share price exceeds the exercise price over a period of 90 consecutive days by at least 20% in the period between the grant date and the respective exercise time frame) which both conditions must be met.

The fair value of the employee share option plan has been measured for Tranches 1 and 2 using a Monte Carlo simulation. The market condition has been incorporated into the fair value at grant date.

The inputs used in the measurement of the fair value at grant date are as follows:

 

 

 

 

 

 

 

Tranche 1

 

Tranche 2

Parameter

 

 

Share price at grant date

 

USD 13.80

 

USD 16.15

Exercise price

 

USD 13.90

 

USD 16.15

Expected volatility

 

55.00%

 

58.40%

Expected dividends

 

 

Risk-free interest rate

 

2.49%

 

2.85%

Fair value at grant date

 

USD 8.00

 

USD 9.74

The respective expected volatility has been based on an evaluation of the historical volatility of the Company’s share price as at the grant date. As at September 30, 2020 no options are exercisable and 353,400 options are outstanding. The weighted-average contractual life of the options at September 30, 2020 amounts to 6.8 years (September 30, 2019: 7.8 years).

The expenses recognized in the profit and loss statement in relation to the share-based payment arrangements amounted to kEUR 169 in the three months and kEUR 501 in the nine months ended September 30, 2020. (Three months and nine months ended September 30, 2019: kEUR 169 and kEUR 501, respectively).

4. Inventories

 

 

 

 

 

 

 

9/30/2020

 

12/31/2019

 

 

(€ in thousands)

Raw materials and merchandise

 

3,947

 

4,109

Work in progress

 

10,052

 

8,350

Total

 

13,999

 

12,459

5. Property, plant and equipment, net

 

 

 

 

 

 

 

9/30/2020

 

12/31/2019

 

 

(€ in thousands)

Land, buildings and leasehold improvements

 

19,081

 

20,045

Plant and machinery

 

4,516

 

5,779

Other facilities, factory and office equipment

 

1,264

 

1,459

Assets under construction and prepayments made

 

58

 

60

Total

 

24,919

 

27,343

Thereof pledged assets of Property, Plant and Equipment

 

13,362

 

6,618

In March 2020, voxeljet registered a first rank land charge amounting to kEUR 10,000 on its land and facility located in Friedberg, Germany as collateral in favor of the European Investment Bank (“EIB”) related to the loan, entered into with the EIB under the Finance Contract, dated November 9, 2017.

6. Other liabilities and provisions

 

 

 

 

 

 

 

9/30/2020

 

12/31/2019

 

 

(€ in thousands)

Liabilities from payroll

 

279

 

301

Accruals for vacation and overtime

 

228

 

190

Employee bonus

 

211

 

397

Accruals for compensation of Supervisory board

 

135

 

180

Accrual for warranty

 

73

 

241

Accruals for licenses

 

48

 

62

Accruals for education and training

 

47

 

Accruals for commissions

 

37

 

38

Liabilities from VAT

 

30

 

32

Accruals for wage continuation

 

26

 

Accruals for employer’s liability insurance coverage

 

15

 

16

Customers with a credit balance

 

13

 

8

Accrual for restructuring

 

2

 

604

Security deposit

 

 

178

Others

 

56

 

82

Total

 

1,200

 

2,329

7. Financial instruments

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. In addition, for the current year the fair value disclosure of lease liabilities is not required.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying amount

 

Fair Value

 

 

 

 

 

 

Assets at

 

Liabilities

 

Total

 

 

 

 

 

 

 

 

 

 

FVTPL

 

FVOCI

 

amortized

 

at amortized

 

carrying

 

 

 

 

 

 

 

 

9/30/2020

 

 

 

 

 

cost

 

cost

 

amount

 

Level 1

 

Level 2

 

Level 3

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

5,975

 

 

5,975

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets

 

2,922

 

 

 

 

2,922

 

2,922

 

 

 

2,922

Bond funds

 

922

 

 

 

 

922

 

922

 

 

 

922

Bond funds (restricted)

 

2,000

 

 

 

 

2,000

 

2,000

 

 

 

2,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade receivables, net

 

 

 

4,630

 

 

4,630

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets

 

2,760

 

5

 

 

 

2,765

 

 

2,760

 

5

 

2,765

Derivative financial instruments

 

2,760

 

 

 

 

2,760

 

 

2,760

 

 

2,760

Equity securities

 

 

5

 

 

 

5

 

 

 

5

 

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

2,095

 

2,095

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial liabilities

 

 

 

 

700

 

1,021

 

 

 

1,151

 

1,151

Long-term debt

 

 

 

 

700

 

700

 

 

 

1,151

 

1,151

Lease liability

 

 

 

 

na

 

321

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial liabilities

 

394

 

 

 

22,175

 

25,542

 

 

394

 

24,730

 

25,124

Derivative financial instruments

 

394

 

 

 

 

394

 

 

394

 

 

394

Long-term debt

 

 

 

 

22,175

 

22,175

 

 

 

24,730

 

24,730

Lease liability

 

 

 

 

na

 

2,973

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Carrying amount

 

Fair Value

 

 

 

 

 

 

Assets at

 

Liabilities

 

Total

 

 

 

 

 

 

 

 

 

 

FVTPL

 

FVOCI

 

amortized

 

at amortized

 

carrying

 

 

 

 

 

 

 

 

12/31/2019

 

 

 

 

 

cost

 

cost

 

amount

 

Level 1

 

Level 2

 

Level 3

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

4,368

 

 

4,368

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets

 

6,945

 

 

463

 

 

7,408

 

6,945

 

 

 

6,945

Bond funds (1)

 

3,667

 

 

 

 

3,667

 

3,667

 

 

 

3,667

Bond funds (restricted) (1)

 

2,000

 

 

 

 

2,000

 

2,000

 

 

 

2,000

Note receivable (1)

 

1,278

 

 

 

 

1,278

 

1,278

 

 

 

1,278

Restricted Cash

 

 

 

463

 

 

463

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade receivables, net

 

 

 

5,915

 

 

5,915

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets

 

2,274

 

 

 

 

2,279

 

 

2,014

 

5

 

2,019

Derivative financial instruments (2)

 

2,274

 

 

 

 

2,274

 

 

2,014

 

 

2,014

Equity securities

 

 

5

 

 

 

5

 

 

 

5

 

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade payables

 

 

 

 

2,797

 

2,797

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial liabilities

 

 

 

 

10,864

 

11,290

 

 

 

10,858

 

10,858

Long-term debt (2) (3)

 

 

 

 

10,864

 

10,864

 

 

 

10,858

 

10,858

Lease liability

 

 

 

 

na

 

426

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-current liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial liabilities

 

 

 

 

6,682

 

9,866

 

 

 

6,148

 

6,148

Long-term debt (2) (3)

 

 

 

 

6,682

 

6,682

 

 

 

6,148

 

6,148

Lease liability

 

 

 

 

na

 

3,184

 

 

 

 

(1)Comparative figures for the year ended December 31, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the year ended December 31, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

(3)Previously presented under level 2.

The valuation techniques used to value financial instruments include the use of quoted market prices or dealer quotes for similar instruments as well as discounted cash flow analysis.

The fair value of the Company’s investments in the bond funds and note receivable was determined based on the quoted unit prices received by the fund management company.

The fair value of the derivative financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. The fair values have been determined based on share prices and the discount rates used were adjusted for counterparty or own credit risk.

The fair value of long-term debt was determined using discounted cash flow models based on the relevant forward interest rate yield curves, considering the credit risk of voxeljet.

Due to their short maturity and the current low level of interest rates, the carrying amounts of cash and cash equivalents, restricted cash, trade receivables, trade payables, credit lines and bank overdrafts approximate fair value.

The group’s policy is to recognize transfers into and transfers out of fair value hierarchy levels as at the end of the reporting period.

In September 2020, there were no transfers of financial instruments measured at fair value between level 1 and level 2.

8. Financial result

 

 

 

 

 

 

 

Three months ended September 30,

 

 

2020

 

2019

 

 

(€ in thousands)

Interest expense

 

(1,005

)

 

(325

)

Interest expense on lease liability

 

(36

)

 

(50

)

Long-term debt

 

(486

)

 

(254

)

Expense from revaluation of derivative financial instruments

 

(481

)

 

 

Other

 

(2

)

 

(21

)

Interest income

 

77

 

 

184

 

Payout of bond funds

 

29

 

 

44

 

Income from revaluation of derivative financial instruments (2)

 

 

 

74

 

Fair value valuation of financial assets (1)

 

47

 

 

63

 

Other

 

1

 

 

3

 

Financial result

 

(928

)

 

(141

)

 

 

 

 

 

 

 

Nine months ended September 30,

 

 

2020

 

2019

 

 

(€ in thousands)

Interest expense

 

(1,692

)

 

(934

)

Interest expense on lease liability

 

(127

)

 

(145

)

Long-term debt (2)

 

(1,094

)

 

(745

)

Expense from revaluation of derivative financial instruments

 

(394

)

 

 

Fair value valuation of financial assets (1)

 

(73

)

 

 

Other

 

(4

)

 

(44

)

Interest income

 

573

 

 

447

 

Payout of bond funds

 

74

 

 

115

 

Income from revaluation of derivative financial instruments (2)

 

486

 

 

133

 

Fair value valuation of financial assets (1)

 

 

 

188

 

Other

 

13

 

 

11

 

Financial result

 

(1,119

)

 

(487

)

(1)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

9. Segment reporting

The following table summarizes segment reporting. The sum of the amounts of the two segments equals the total for the Group in each of the periods.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30,

 

 

2020

 

 

 

 

2019

 

 

 

 

 

(€ in thousands)

 

 

 

 

 

 

CONSO

 

 

 

 

 

 

 

CONSO

 

 

 

 

SYSTEMS

 

SERVICES

 

LIDATION

 

GROUP

 

SYSTEMS

 

SERVICES

 

LIDATION

 

GROUP

Revenues

 

2,836

 

 

2,222

 

 

(150

)

 

4,908

 

 

1,966

 

 

2,800

 

 

(330

)

 

4,436

 

third party

 

2,686

 

 

2,222

 

 

 

 

4,908

 

 

1,636

 

 

2,800

 

 

 

 

4,436

 

intra-segment

 

150

 

 

 

 

(150

)

 

 

 

330

 

 

 

 

(330

)

 

 

Cost of sales

 

(1,626

)

 

(1,675

)

 

 

 

(3,301

)

 

(1,279

)

 

(2,292

)

 

 

 

(3,571

)

Gross profit

 

1,060

 

 

547

 

 

 

 

1,607

 

 

357

 

 

508

 

 

 

 

865

 

Gross profit in %

 

39.5

%

 

24.6

%

 

 

 

32.7

%

 

21.8

%

 

18.1

%

 

 

 

19.5

%

Operating Expenses

 

 

 

 

 

 

 

(4,254

)

 

 

 

 

 

 

 

(5,142

)

Other operating expenses

 

 

 

 

 

 

 

(590

)

 

 

 

 

 

 

 

(36

)

Other operating income

 

 

 

 

 

 

 

223

 

 

 

 

 

 

 

 

787

 

Operating loss

 

 

 

 

 

 

 

(3,014

)

 

 

 

 

 

 

 

(3,526

)

Finance expense (1) (2)

 

 

 

 

 

 

 

(1,005

)

 

 

 

 

 

 

 

(325

)

Finance income (1) (2)

 

 

 

 

 

 

 

77

 

 

 

 

 

 

 

 

184

 

Financial result

 

 

 

 

 

 

 

(928

)

 

 

 

 

 

 

 

(141

)

Loss before income taxes

 

 

 

 

 

 

 

(3,942

)

 

 

 

 

 

 

 

(3,667

)

Income tax income (expense) (2)

 

 

 

 

 

 

 

(93

)

 

 

 

 

 

 

 

(68

)

Net loss

 

 

 

 

 

 

 

(4,035

)

 

 

 

 

 

 

 

(3,735

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine months ended September 30,

 

 

2020

 

 

 

 

2019

 

 

 

 

 

(€ in thousands)

 

 

 

 

 

 

CONSO

 

 

 

 

 

 

 

CONSO

 

 

 

 

SYSTEMS

 

SERVICES

 

LIDATION

 

GROUP

 

SYSTEMS

 

SERVICES

 

LIDATION

 

GROUP

Revenues

 

6,437

 

 

6,846

 

 

(575

)

 

12,708

 

 

6,777

 

 

8,871

 

 

(597

)

 

15,051

 

third party

 

5,862

 

 

6,846

 

 

 

 

12,708

 

 

6,180

 

 

8,871

 

 

 

 

15,051

 

intra-segment

 

575

 

 

 

 

(575

)

 

 

 

597

 

 

 

 

(597

)

 

 

Cost of sales

 

(3,822

)

 

(5,109

)

 

 

 

(8,931

)

 

(4,463

)

 

(6,284

)

 

 

 

(10,747

)

Gross profit

 

2,040

 

 

1,737

 

 

 

 

3,777

 

 

1,717

 

 

2,587

 

 

 

 

4,304

 

Gross profit in %

 

34.8

%

 

25.4

%

 

 

 

29.7

%

 

27.8

%

 

29.2

%

 

 

 

28.6

%

Operating Expenses

 

 

 

 

 

 

 

(13,567

)

 

 

 

 

 

 

 

(15,011

)

Other operating expenses

 

 

 

 

 

 

 

(1,958

)

 

 

 

 

 

 

 

(422

)

Other operating income

 

 

 

 

 

 

 

1,258

 

 

 

 

 

 

 

 

1,468

 

Operating loss

 

 

 

 

 

 

 

(10,490

)

 

 

 

 

 

 

 

(9,661

)

Finance expense (1) (2)

 

 

 

 

 

 

 

(1,692

)

 

 

 

 

 

 

 

(934

)

Finance income (1) (2)

 

 

 

 

 

 

 

573

 

 

 

 

 

 

 

 

447

 

Financial result

 

 

 

 

 

 

 

(1,119

)

 

 

 

 

 

 

 

(487

)

Loss before income taxes

 

 

 

 

 

 

 

(11,609

)

 

 

 

 

 

 

 

(10,148

)

Income tax income (expense) (2)

 

 

 

 

 

 

 

(150

)

 

 

 

 

 

 

 

(123

)

Net loss

 

 

 

 

 

 

 

(11,759

)

 

 

 

 

 

 

 

(10,271

)

(1)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the amendment of classification of short-term investments. For further information, see Note 1 of the interim consolidated financial statements.

(2)Comparative figures for the three and nine months ended September 30, 2019 were revised related to the recalculation of the performance participation interest related to the Finance Contract with the EIB. For further information, see Note 1 of the interim consolidated financial statements.

10. Revenues

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30,

 

 

2020

 

2019

 

2020

 

2019

 

 

SYSTEMS

 

SERVICES

 

 

(€ in thousands)

Primary geographical markets

 

 

 

 

 

 

 

 

EMEA

 

1,025

 

946

 

1,364

 

1,639

Asia Pacific

 

309

 

221

 

223

 

212

Americas

 

1,352

 

469

 

635

 

949

 

 

2,686

 

1,636

 

2,222

 

2,800

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

Products transferred at a point in time

 

2,392

 

1,235

 

2,222

 

2,800

Products and services transferred over time

 

294

 

401

 

 

Revenue from contracts with customers

 

2,686

 

1,636

 

2,222

 

2,800

 

 

 

 

 

 

 

 

 

 

 

Nine months ended September 30,

 

 

2020

 

2019

 

2020

 

2019

 

 

SYSTEMS

 

SERVICES

 

 

(€ in thousands)

Primary geographical markets

 

 

 

 

 

 

 

 

EMEA

 

3,290

 

2,782

 

4,190

 

5,119

Asia Pacific

 

704

 

1,151

 

683

 

712

Americas

 

1,868

 

2,247

 

1,973

 

3,040

 

 

5,862

 

6,180

 

6,846

 

8,871

 

 

 

 

 

 

 

 

 

Timing of revenue recognition

 

 

 

 

 

 

 

 

Products transferred at a point in time

 

5,074

 

5,360

 

6,846

 

8,871

Products and services transferred over time

 

788

 

820

 

 

Revenue from contracts with customers

 

5,862

 

6,180

 

6,846

 

8,871

 

 

 

 

 

 

 

 

 

 

 

Three months ended September 30,

 

Nine months ended September 30,

 

 

2020

 

2019

 

2020

 

2019

 

 

(€ in thousands)

EMEA

 

2,389

 

2,585

 

7,480

 

7,901

Germany

 

834

 

1,231

 

3,644

 

3,606

France

 

189

 

399

 

686

 

1,039

Switzerland

 

102

 

54

 

195

 

494

Great Britain

 

205

 

270

 

765

 

980

Others

 

1,059

 

631

 

2,190

 

1,782

Asia Pacific

 

532

 

433

 

1,387

 

1,863

China

 

326

 

242

 

816

 

734

South Korea

 

160

 

134

 

428

 

481

Others

 

46

 

57

 

143

 

648

Americas

 

1,987

 

1,418

 

3,841

 

5,287

United States

 

1,981

 

1,289

 

3,722

 

5,096

Others

 

6

 

129

 

119

 

191

Total

 

4,908

 

4,436

 

12,708

 

15,051

11. Commitments, contingent assets and liabilities

In March 2018, ExOne GmbH, a subsidiary of ExOne, notified voxeljet of its intent not to pay its annual license fees under an existing intellectual property-related agreement and asserted its rights to claim damages pursuant to an alleged material breach of the agreement. At this time, the Company cannot reasonably estimate a contingency, if any, related to this matter.

In connection with the enforcement of voxeljet’s intellectual property rights, the acquisition of third‑party intellectual property rights, or disputes related to the validity or alleged infringement of the Company’s or a third‑party’s intellectual property rights, including patent rights, voxeljet has been and may in the future be subject or party to claims, negotiations or complex, protracted litigation.

12. Related party transactions

 

 

 

 

 

Name

 

Nature of relationship

 

Duration of relationship

Franz Industriebeteiligungen AG, Augsburg

 

Lessor

 

10/01/2003 – Current

Schlosserei und Metallbau Ederer, Dießen

 

Supplier

 

05/01/1999 – Current

Andreas Schmid Logistik AG, Gersthofen

 

Supplier

 

05/01/2017 – Current

Suzhou Meimai Fast Manufacturing Technology Co., Ltd, Suzhou

 

Minority shareholder of voxeljet China, Customer

 

04/11/2016 – Current

DSCS Digital Supply Chain Solutions GmbH, Gersthofen

 

Customer

 

05/11/2017 – Current

Michele Neuber

 

Employee

 

07/01/2019 – Current

Transactions with Franz Industriebeteiligungen AG comprise the rental of office space in Augsburg, Germany. Rental expenses amounted to kEUR 2, in each, the nine months ended September 30, 2020 as well as the nine months ended September 30, 2019.

Furthermore, voxeljet acquired goods amounting to kEUR 0 and kEUR 0 in the nine months ended September 30, 2020 and 2019, respectively from ‘Schlosserei und Metallbau Ederer’, which is owned by the brother of Dr. Ingo Ederer, the Chief Executive Officer of voxeljet.

In addition, voxeljet received logistics services amounting to kEUR 25 and kEUR 43 in the nine months ended September 30, 2020 and 2019, respectively from ‘Andreas Schmid Logistik’, where the member of our supervisory board Dr. Stefan Söhn serves as the Chief Financial Officer.

Moreover, voxeljet received orders amounting to kEUR 19 and kEUR 136 in the nine months ended September 30, 2020 and 2019, respectively from ‘Suzhou Meimai Fast Manufacturing Technology Co., Ltd., which is our minority shareholder for voxeljet China.

Further, voxeljet received orders amounting to kEUR 0 and kEUR 11 in the in the nine months ended September 30, 2020 and 2019, respectively from ‘DSCS Digital Supply Chain Solutions GmbH’, which is an associated company where we own 33.3%.

In addition, voxeljet employed Michele Neuber as an intern, the son of Volker Neuber, who is member of our supervisory board since July 2020. He received a salary of kEUR 1 and kEUR 1 in the nine months ended September 30, 2020 and 2019, respectively.

All related party transactions, voxeljet entered into, were made on an arm’s length basis.

13. Subsequent events

By resolution of its supervisory board dated November 12, 2020, the current members of the Company’s management board, Dr. Ingo Ederer and Rudolf Franz, were reappointed as members of the management board for a new three year term from July 1, 2021 until June 30, 2024. Dr. Ingo Ederer and Rudolf Franz have each accepted such new appointment.

Following the reappointment of Dr. Ingo Ederer and Rudolf Franz as members of the management board, each of Dr. Ingo Ederer and Rudolf Franz entered into a new three year service agreement effective as of July 1, 2021. The current service agreements will expire at the end of their current term of office on June 30, 2021.

The main terms of the service agreements are summarized below. The terms of the service agreements of Dr. Ingo Ederer and Rudolf Franz are identical with only a few deviating provisions regarding the company car and social security payments.

Each service agreement can be terminated prior to June 30, 2024 only, (i) by the member of the management board exercising a special termination right (Sonderkündigungsrecht) in case of a change of control of voxeljet (as defined in the service agreement), if and to the extend such change of control leads to a material change of the position of the member of the management board, if (ii) the member of the management board is terminated by the Company for cause or if (iii) the member of the management board terminates the service agreement for cause.

If a member of the management board terminates the service agreement exercising the special termination right (Sonderkündigungsrecht) in case of a change of control, the member of the management board is entitled to a compensation payment. Such compensation payment consists of the sum of 50% of the total remuneration payable to the member of the management board over the outstanding full term of the service agreement (fixed plus variable remuneration assuming the full achievement of all bonus targets) and a lump sum payment amounting to two annual fixed salaries. The compensation payment is capped at the amount of EUR 1,425,000.

Under German law, a contract can be terminated for cause only in exceptional circumstances (i.e., if the continuation of the contractual relationship is unacceptable for the terminating party). Termination for cause generally requires that a party repeatedly and severely breaches its contractual duties. To the extent the employment terminates during a business year, the member of the management board is entitled to a pro rata portion of the bonus that reflects the percentage of the year that the member of the management board worked for the Company.

Furthermore, each service agreement contains a covenant pursuant to which each member of the management board has agreed not to compete with the Company for a period of two years after the termination of the service agreement. Under German law, a non-compete covenant is only valid if the employee is compensated during the term of the non-compete obligation. As compensation for the non-compete covenant, each member of the management board will receive 100% of his fixed salary (but in no event less than 50% of the total compensation received in the preceding year) for the entire two year term of the non-compete covenant. If the service agreement of a member of the management board is terminated for cause, the Company is not obligated to pay the compensation for the non-compete covenant, so long as the Company provides the member of the management board with a written statement disclaiming the Company’s obligation to pay this compensation within one month after the termination.

The new service agreements provide for an annual fixed compensation (base salary), an annual performance award (annual bonus) with a target of up to 30% of the yearly base salary, as well as a long-term performance award for a three-business-year period (long-term bonus) with a target of up to 100% of the yearly base salary. The performance targets of the annual and long-term bonuses are a mixture of certain financial and non-financial targets, such as revenue, profitability and liquidity targets as well as personal goals. In addition to the fixed and variable remuneration components, each member of the management board is entitled to additional benefits (including company car arrangements, mobile phone, accident and director and officer liability insurance) and reimbursement of necessary and reasonable expenses. In addition, the supervisory board can grant stock options to the members of the management board on the basis of a stock option plan.

Based on the aforementioned fixed and variable bonus payments and the perquisites related to company car, each of Dr. Ederer and Mr. Franz would be entitled to a maximum compensation of up to EUR 491,400 per year of the agreement.

The foregoing description of the service agreements is qualified in its entirety by reference to the full text of each of Dr. Ingo Ederer’s and Rudolf Franz’s service agreement, copies of which are attached hereto as Exhibit 10.1 and 10.2, respectively, and incorporated herein by reference.

Investors and Media

Johannes Pesch

Director Investor Relations and Business Development

[email protected]

Office: +49 821 7483172

Mobile: +49 176 45398316

KEYWORDS: New York Germany Europe United States North America

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Technology Manufacturing Other Technology Other Manufacturing Hardware

MEDIA:

Logo
Logo

Scott’s Liquid Gold-Inc. Reports Third Quarter Results

Scott’s Liquid Gold-Inc. Reports Third Quarter Results

Third Quarter 2020 Highlights:

  • Net sales of $7.2 million, negatively impacted by COVID-related supply chain issues, partially offset by Biz and Dryel acquisition
  • Net loss of $0.5 million (($0.04) per share)
    • Includes $0.3 million of expenses related to supply chain transition and Biz and Dryel acquisition
  • Gross margin of 44.8%, an increase of 3.8% from Q3 2019

DENVER–(BUSINESS WIRE)–
Scott’s Liquid Gold-Inc. (OTC: SLGD) today announced operating results for the three months ended September 30, 2020.

President and Chief Executive Officer Mark Goldstein stated, “As we previously announced, pandemic driven raw material and container shortages impacted our third quarter revenue. We have seen limited improvements throughout our supply chain and expect better results in the fourth quarter, though challenges remain.”

Net Sales

Net sales remained level for three months ended September 30, 2020 compared to last year because a decrease in sales due to COVID-driven supply chain shortages was offset by an increase in net sales due to our Kids N Pets, Biz and Dryel acquisitions.

Net sales for the nine months ended September 30, 2020 increased $0.8 million compared to last year due to our Kids N Pets, Biz and Dryel acquisitions, partially offset by decreased sales for multiple product lines due to COVID-related shortages.

Net Loss

Our net loss of $0.5 million for the three months ended September 30, 2020 was primarily driven by COVID-related supply chain issues, increased SG&A expenses attributable to supply chain transition, acquisition-related expenses and interest expense associated with our new debt. These were partially offset by an increase in gross profit driven by the introduction of our Kids N Pets and SLG One products during the fourth quarter of 2019, the introduction of our Biz and Dryel products during the third quarter of 2020, and margin increases associated with outsourcing.

We reported a $0.4 million decrease in net loss for the nine months ended 2020 compared to last year due to our Kids N Pets, Biz and Dryel acquisitions, improved margins due to outsourcing our manufacturing, and a $0.4 million transition payment received related to the termination of our MJ distribution agreement. These decreases in net loss were partially offset by decreased sales caused by COVID-related reduced store traffic and raw material supply chain issues, increased SG&A due to supply chain transition and acquisition-related expenses, gain on sale of equipment during 2019, and interest expense associated with our new debt.

Cash Flow

Cash flow provided by operating activities was $4.3 million for the nine months ended September 30, 2020, as compared to cash flow provided from operating activities of $1.1 million for the same 2019 period. The $3.2 million increase in operating cash flow was primarily the result of our Kids N Pets, Biz, and Dryel acquisitions, as well as our improved margins driven by cost savings from outsourcing.

About Scott’s Liquid Gold-Inc.

Scott’s Liquid Gold-Inc. develops, markets, and sells high-quality, high-value household and personal care products nationally and internationally to mass merchandisers, drugstores, supermarkets, hardware stores, e-commerce retailers, other retail outlets, and to wholesale distributors. Over the last 65+ years we have developed a reputation for delivering products that consumers know and trust.

Our flagship product, Scott’s Liquid Gold® Wood Care, is a leader in its category and is known for bringing life back to and protecting all types of natural wood surfaces. Our Kids N Pets® brands are award winning, safe, nontoxic, stain and odor removing products targeted toward households with children and pets. Our newly acquired Biz and Dryel are top performing laundry care products, with Biz being a top stain removing laundry additive, and Dryel being the market leader in at-home dry cleaning.

Scott’s Liquid Gold-Inc. also owns Neoteric Cosmetics, a personal care company with a rich history of offering products that deliver high-quality, proven results that customers expect. Neoteric’s personal care products are embraced and respected by both medical professionals and consumers alike and include brands such as Alpha® Skin Care, Prell®, and Denorex®. Neoteric Cosmetics is also the proud American specialty channel distributor for Batiste Dry Shampoo.

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net sales

$

7,197

 

 

$

7,178

 

 

$

21,134

 

 

$

20,365

 

Cost of sales

 

3,973

 

 

 

4,235

 

 

 

11,578

 

 

 

12,877

 

Gross Profit

 

3,224

 

 

 

2,943

 

 

 

9,556

 

 

 

7,488

 

Gross Margin

 

44.8

%

 

 

41.0

%

 

 

45.2

%

 

 

36.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advertising

 

169

 

 

 

105

 

 

 

531

 

 

 

491

 

Selling

 

2,168

 

 

 

1,369

 

 

 

5,371

 

 

 

4,381

 

General and administrative

 

1,377

 

 

 

1,223

 

 

 

4,284

 

 

 

3,604

 

Total operating expenses

 

3,714

 

 

 

2,697

 

 

 

10,186

 

 

 

8,476

 

(Loss) income from operations

 

(490

)

 

 

246

 

 

 

(630

)

 

 

(988

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

 

28

 

 

 

3

 

 

 

89

 

Interest expense

 

(137

)

 

 

(5

)

 

 

(215

)

 

 

(14

)

Gain on sale of equipment

 

 

 

 

 

 

 

 

 

 

 

110

 

Other income

 

 

 

 

 

 

 

350

 

 

 

 

(Loss) income before income taxes

 

(627

)

 

 

269

 

 

 

(492

)

 

 

(803

)

Income tax benefit

 

110

 

 

 

118

 

 

 

174

 

 

 

144

 

Net (loss) income

$

(517

)

 

$

387

 

 

$

(318

)

 

$

(659

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per common share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.04

)

 

$

0.03

 

 

$

(0.03

)

 

$

(0.05

)

Diluted

$

(0.04

)

 

$

0.03

 

 

$

(0.03

)

 

$

(0.05

)

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

12,480

 

 

 

12,462

 

 

 

12,468

 

 

 

12,435

 

Diluted

 

12,480

 

 

 

12,462

 

 

 

12,468

 

 

 

12,435

 

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except par value amounts)

 

September 30,

 

 

December 31,

 

 

2020

 

 

2019

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

174

 

 

$

1,094

 

Accounts receivable, net

 

4,451

 

 

 

2,695

 

Inventories, net

 

5,747

 

 

 

7,841

 

Income taxes receivable

 

107

 

 

 

705

 

Property and equipment held for sale

 

 

 

 

500

 

Prepaid expenses

 

701

 

 

 

368

 

Other current assets

 

 

 

 

71

 

Total current assets

 

11,180

 

 

 

13,274

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

129

 

 

 

124

 

Deferred tax asset

 

692

 

 

 

556

 

Goodwill

 

5,280

 

 

 

3,230

 

Intangible assets, net

 

15,105

 

 

 

8,719

 

Operating lease right-of-use assets

 

3,048

 

 

 

188

 

Other assets

 

38

 

 

 

 

Total assets

$

35,472

 

 

$

26,091

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

2,959

 

 

$

1,809

 

Accrued expenses

 

589

 

 

 

422

 

Current portion of long-term debt

 

1,000

 

 

 

 

Operating lease liabilities, current portion

 

301

 

 

 

197

 

Total current liabilities

 

4,849

 

 

 

2,428

 

 

 

 

 

 

 

 

 

Long-term debt, net of current portion and debt issuance costs

 

4,031

 

 

 

 

Operating lease liabilities, net of current

 

2,977

 

 

 

19

 

Other liabilities

 

143

 

 

 

27

 

Total liabilities

 

12,000

 

 

 

2,474

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

Preferred stock, no par value, authorized 20,000 shares; no shares issued and outstanding

 

 

 

 

 

Common stock; $0.10 par value, authorized 50,000 shares; issued and outstanding 12,513 shares (2020) and 12,462 shares (2019)

 

1,251

 

 

 

1,246

 

Capital in excess of par

 

7,418

 

 

 

7,250

 

Retained earnings

 

14,803

 

 

 

15,121

 

Total shareholders’ equity

 

23,472

 

 

 

23,617

 

Total liabilities and shareholders’ equity

$

35,472

 

 

$

26,091

 

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

Nine Months Ended

 

 

September 30,

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

$

(318

)

 

$

(659

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

976

 

 

 

552

 

Stock-based compensation

 

106

 

 

 

119

 

Deferred income taxes

 

(136

)

 

 

(150

)

Gain on sale of equipment

 

 

 

 

(110

)

Change in operating assets and liabilities, net of effects of acquisition:

 

 

 

 

 

 

 

Accounts receivable

 

(1,756

)

 

 

336

 

Inventories

 

3,373

 

 

 

787

 

Prepaid expenses and other assets

 

(200

)

 

 

196

 

Income taxes receivable

 

598

 

 

 

1

 

Accounts payable, accrued expenses, and other liabilities

 

1,659

 

 

 

40

 

Total adjustments to net loss

 

4,620

 

 

 

1,771

 

Net cash provided by operating activities

 

4,302

 

 

 

1,112

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Acquisition

 

(10,529

)

 

 

 

Proceeds from sale of property and equipment

 

500

 

 

 

110

 

Purchase of internal-use software

 

 

 

 

(286

)

Purchase of property and equipment

 

(17

)

 

 

(101

)

Cash paid for leasehold improvements

 

(484

)

 

 

 

Reimbursement for leasehold improvements

 

247

 

 

 

 

Net cash used in investing activities

 

(10,283

)

 

 

(277

)

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from revolving credit facility

 

6,525

 

 

 

 

Repayments of revolving credit facility

 

(3,795

)

 

 

 

Proceeds from term loan

 

3,000

 

 

 

 

Repayments of term loan

 

(167

)

 

 

 

Proceeds from PPP loan

 

600

 

 

 

 

Repayment of PPP loan

 

(600

)

 

 

 

Payments for debt issuance costs

 

(569

)

 

 

 

Proceeds from exercise of stock options

 

67

 

 

 

43

 

Net cash provided by financing activities

 

5,061

 

 

 

43

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

 

(920

)

 

 

878

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

1,094

 

 

 

6,232

 

Cash and cash equivalents, end of period

$

174

 

 

$

7,110

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

Cash paid during the period for interest

$

23

 

 

$

14

 

Note Regarding Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “assumptions,” “target,” “guidance,” “strategy,” “outlook,” “plans,” “projection,” “may,” “will,” “would,” “expect,” “intend,” “estimate,” “anticipate,” “believe”, “potential,” or “continue” (or the negative or other derivatives of each of these terms) or similar terminology.

Forward-looking statements convey our expectations, intentions, or forecasts about future events, circumstances, or results. All forward-looking statements, by their nature, are subject to assumptions, risks, and uncertainties, which may change over time and many of which are beyond our control. You should not rely on any forward-looking statement as a prediction or guarantee about the future. Actual future objectives, strategies, plans, prospects, performance, conditions, or results may differ materially from those set forth in any forward-looking statement. Some of the factors that may cause actual results or other future events or circumstances to differ from those in forward-looking statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s subsequent Quarterly Reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statement made by us or on our behalf speaks only as of the date that it was made. We do not undertake to update any forward-looking statement to reflect the impact of events, circumstances, or results that arise after the date that the statement was made, except as required by applicable securities laws. You, however, should consult further disclosures (including disclosures of a forward-looking nature) that we may make in any subsequent filings with the Securities and Exchange Commission.

Investor Relations Contact:

Kevin Paprzycki, CFO

303.576.6032

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Home Goods Retail Specialty

MEDIA:

Logo
Logo

New SP+ Shuttle Operations Begin at Salt Lake City International Airport

CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — SP Plus Corporation (SP+), (Nasdaq: SP), a leading provider of technology-driven mobility solutions for aviation, commercial, hospitality and institutional clients throughout North America, today announced its commencement of shuttle bus operations at the newly-reconstructed Salt Lake City International Airport (SLC) in Utah.

SP+ hired more than 75 employees to effectively operate a new shuttle program at SLC, which includes 39 buses. The shuttle routes transport passengers around the airport’s premises, smoothly moving people to-and-from the airport terminals and the multi-gate hardstands where they board their airplanes.

In addition to the new shuttle program designed to serve travelers as they move through the air operations area, SP+ already provides comprehensive parking, shuttle and ground transportation management services for SLC.

“SP+ is excited to expand our role in working with the Salt Lake City Airport Authority by making the experience for passengers even easier and more enjoyable at this incredible new airport project,” added Jason Finch, Senior Vice President, West Airports at SP+.


SP+ 

facilitates the efficient movement of people, vehicles and personal belongings with the goal of enhancing the consumer experience while improving bottom line results for our clients. The Company provides professional parking management, ground transportation, remote baggage check-in and handling, facility maintenance, security, event logistics, and other technology-driven mobility solutions to aviation, commercial, hospitality, healthcare and government clients
across North America. For more
information
,
visit www.spplus.com.

CONTACT: Jill Nagel
  Senior Communications Manager
  [email protected], 312-274-2102

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

— Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 —

BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

As previously reported, the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, change from baseline in the North Star Ambulatory Assessment, over one year of treatment compared to placebo. The secondary endpoint timed function tests also did not show statistically significant improvements. Edasalonexent was observed to be generally safe and well-tolerated in this trial, consistent with the safety profile seen to date. As previously announced, Catabasis is stopping activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial.

Catabasis has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for the previously announced plan to explore and evaluate strategic options. Potential strategic options that may be evaluated include a merger, business combination, in-licensing, out-licensing or other strategic transaction. There can be no assurance that this process will result in any such transaction. We do not intend to discuss or disclose further developments during this process unless and until our Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate.

Third Quarter 2020 Financial Results

Cash Position: As of September 30, 2020, Catabasis had cash, cash equivalents and short-term investments of $52.9 million, compared to $53.9 million as of June 30, 2020. Based on the Company’s current operating plan, Catabasis expects that it has sufficient cash to fund operations for at least the next 12 months. Net cash used in operating activities for the three months ended September 30, 2020 was $10.0 million, compared to $6.5 million for the three months ended September 30, 2019.

R&D Expenses: Research and development expenses were $7.8 million for the three months ended September 30, 2020, compared to $4.7 million for the three months ended September 30, 2019.

G&A Expenses: General and administrative expenses were $3.1 million for the three months ended September 30, 2020, compared to $2.0 million for the three months ended September 30, 2019.

Operating Loss: Loss from operations was $10.9 million for the three months ended September 30, 2020, compared to $6.7 million for the three months ended September 30, 2019.

Net Loss: Net loss was $10.9 million, or $0.56 per share, for the three months ended September 30, 2020, compared to a net loss of $6.5 million, or $0.56 per share, for the three months ended September 30, 2019.

About Catabasis

Catabasis Pharmaceuticals is a biopharmaceutical company. Our mission is to bring hope with life-changing therapies to patients and families.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about its exploration and evaluation of strategic options, the termination of activities related to the edasalonexent program, including the ongoing GalaxyDMD open-label extension trial, and cash to fund operations, and other statements containing the words “believes,” “anticipates,” “plans,” “hopes,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of applicable securities laws and regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: the impact of the COVID-19 pandemic and the effectiveness of the steps we have implemented to address the pandemic; the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; unexpected costs or expenses, including any that arise during the termination of activities related to the edasalonexent program; risks inherent in the Company’s exploration, evaluation and implementation of its review of strategic options; and general market and economic conditions; and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Catabasis Pharmaceuticals, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

2020

 

2019

 

2020

 

2019

 
Operating expenses:
Research and development

$

7,806

 

$

4,697

 

$

19,845

 

$

14,054

 

General and administrative

 

3,057

 

 

1,985

 

 

8,612

 

 

6,287

 

Total operating expenses

 

10,863

 

 

6,682

 

 

28,457

 

 

20,341

 

Loss from operations

 

(10,863

)

 

(6,682

)

 

(28,457

)

 

(20,341

)

Other income (expense):
Interest and investment income

 

4

 

 

214

 

 

231

 

 

697

 

Other expense, net

 

(3

)

 

(46

)

 

(96

)

 

(39

)

Total other income, net

 

1

 

 

168

 

 

135

 

 

658

 

Net loss

$

(10,862

)

$

(6,514

)

$

(28,322

)

$

(19,683

)

Net loss per share – basic and diluted

$

(0.56

)

$

(0.56

)

$

(1.59

)

$

(1.80

)

Weighted-average common shares outstanding used in net loss per share – basic and diluted

 

19,424,866

 

 

11,624,232

 

 

17,769,738

 

 

10,945,765

 

 

Catabasis Pharmaceuticals, Inc.

Selected Consolidated Balance Sheets Data

(In thousands)

(Unaudited)

 

September 30,

 

December 31,

2020

 

2019

Assets
Cash and cash equivalents

$

52,856

$

9,899

Short-term investments

 

 

 

26,345

 

Right-of-use asset

 

1,178

 

 

2,349

 

Other current and long-term assets

 

2,816

 

 

3,187

 

Total assets

 

56,850

 

 

41,780

 

Liabilities and stockholders’ equity
Current portion of operating lease liabilities

 

648

 

 

1,225

 

Long-term portion of operating lease liabilities

 

559

 

 

1,028

 

Other current and long-term liabilities

 

6,332

 

 

3,807

 

Total liabilities

 

7,539

 

 

6,060

 

Total stockholders’ equity

$

49,311

 

$

35,720

 

 

Catabasis Pharmaceuticals, Inc.

Selected Consolidated Statements of Cash Flows Data

(In thousands)

(Unaudited)

 

Nine Months Ended September 30,

2020

 

2019

Net cash used in operating activities

$

(24,424

)

$

(18,799

)

Net cash provided by (used) in investing activities

 

26,310

 

 

(578

)

Net cash provided by financing activities

 

40,829

 

 

21,848

 

Net increase in cash, cash equivalents and restricted cash

$

42,715

 

$

2,471

 

 

Investor relations:

Andrea Matthews

[email protected]

Media:

Elizabeth Higgins

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo

Navient declares fourth quarter common stock dividend

WILMINGTON, Del., Nov. 12, 2020 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI), a leader in education loan management and business processing solutions, announced that its board of directors approved a 2020 fourth quarter dividend of $0.16 per share on the company’s common stock.

The fourth quarter 2020 dividend will be paid on December 18, 2020, to shareholders of record at the close of business on December 4, 2020.

About Navient

Navient (Nasdaq: NAVI) is a leading provider of education loan management and business processing solutions for education, healthcare, and government clients at the federal, state, and local levels. Navient helps clients and millions of Americans achieve success through technology-enabled financing, services, and support. Learn more at Navient.com.

Contact:

Media: Paul Hartwick, 302-283-4026, [email protected]

Investors: Nathan Rutledge, 703-984-6801, [email protected]

NAVICF

Berkeley Lights Reports Financial Results for Third Quarter of Fiscal Year 2020

EMERYVILLE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended September 30, 2020.

Recent Highlights

  • Total revenue of $18.2 million for the third quarter, representing a 16% increase over the same period in 2019 and a 72% increase compared to the second quarter of 2020
  • Released Opto Cell Line Development 2.0 Workflow which enables higher throughput, assays for complex proteins such as multi-specifics, and acceleration of our customers’ path to production cell lines
  • Released new assays for Cell Therapy which drove more than a third of the quarter’s total platform placements

Third Quarter 2020 Financial Results

Revenue was $18.2 million for the quarter ended September 30, 2020, representing a 16% increase from the third quarter in the prior year. Product revenue was $14.1 million for the quarter, representing a 7% increase from the third quarter in the prior year. Service revenue was $4.1 million for the quarter, representing a 66% increase from the third quarter in the prior year.

Direct platform revenue was $12.4 million for the quarter, compared to $12.3 million for the third quarter in the prior year. Recurring revenue was $3.7 million for the quarter, compared to $1.9 million for the third quarter in the prior year. Milestone and related revenue was $2.1 million for the quarter, compared to $1.5 million for the third quarter in the prior year.

Gross profit was $12.8 million for the third quarter of 2020, up $1.1 million from $11.7 million for the corresponding prior year period. Gross margin was 70% for the third quarter of 2020, compared to 74% for the corresponding prior year period. 

Operating expenses were $21.0 million for the third quarter of 2020, compared to $15.9 million in the third quarter of the prior year, representing an increase of approximately 32%.

Net loss was $8.6 million in the third quarter of 2020, compared to $4.4 million in the same period in 2019.

Cash and cash equivalents were $237.2 million as of September 30, 2020 including $187.9 million of net proceeds from the Company’s IPO in mid-July.

Webcast and Conference Call Information

Berkeley Lights will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 12, 2020 at 1:30 PM Pacific Time/4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.            

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. 

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Press Contact

[email protected]

Investor Contact

[email protected]

Berkeley Lights, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except share and per share data)

  Three months ended September 30,
  2020   2019
       
Revenue:      
Product revenue $ 14,103     $ 13,200  
Service revenue 4,105     2,467  
Total revenue 18,208     15,667  
Cost of sales:      
Product cost of sales 3,463     3,387  
Service cost of sales 1,937     610  
Total cost of sales 5,400     3,997  
Gross profit 12,808     11,670  
Operating expenses:      
Research and development 10,421     10,189  
General and administrative 7,229     3,136  
Sales and marketing 3,341     2,623  
Total operating expenses 20,991     15,948  
Loss from operations (8,183 )   (4,278 )
Other income (expense):      
Interest expense (361 )   (360 )
Interest income 51     221  
Other income (expense), net 10     (10 )
Loss before income taxes (8,483 )   (4,427 )
Provision for income taxes 118     21  
Net loss and net comprehensive loss $ (8,601 )   $ (4,448 )
       
Net loss attributable to common stockholders per share, basic and diluted $ (0.16 )   $ (1.78 )
Weighted-average shares used in calculating net loss per share, basic and diluted 53,596,982     2,943,162  
           

Berkeley Lights, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

Assets September 30,

2020
  December 31,

2019
  (unaudited)    
Current assets:      
Cash and cash equivalents $ 237,233     $ 81,033  
Trade accounts receivable 12,702     9,334  
Inventory 12,839     7,181  
Prepaid expenses and other current assets 8,682     7,799  
Total current assets 271,456     105,347  
Restricted cash 270     270  
Property and equipment, net 14,564     16,472  
Operating lease right-of-use assets 12,736     7,785  
Other assets 984     1,135  
Total assets $ 300,010     $ 131,009  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Trade accounts payable $ 4,178     $ 3,239  
Accrued expenses and other current liabilities 8,314     6,229  
Current portion of notes payable 6,595     5,765  
Deferred revenue 4,704     9,686  
Total current liabilities 23,791     24,919  
Notes payable, net of current portion 13,283     14,062  
Deferred revenue, net of current portion 1,168     1,461  
Lease liability, long-term 11,185     6,784  
Total liabilities 49,427     47,226  
Stockholders’ equity:      
Convertible preferred stock     224,769  
Common stock 3      
Additional paid-in capital 430,336     9,314  
Accumulated deficit (179,756 )   (150,300 )
Total stockholders’ equity 250,583     83,783  
Total liabilities and stockholders’ equity $ 300,010     $ 131,009  

Sun BioPharma, Inc. Provides Business Update and Reports Q3 2020 Financial Results

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2020. Management is hosting an earnings call today at 4:30 p.m. ET.

The third quarter of 2020 was marked by meaningful corporate, financial and clinical progress.

Highlights

  • New CEO appointed on July 15, 2020
  • Fast Track designation received for SBP-101
  • Uplisted to Nasdaq Capital Market
  • Closed $10.5 Million Public Offering

“During the third quarter we strengthened our leadership team, bolstered the balance sheet and broadened our potential investor audience by uplisting to Nasdaq,” said Jennifer K. Simpson, PhD, MSN, CRNP President & Chief Executive Officer of Sun BioPharma. “These Q3 accomplishments lay the foundation to execute on near-term milestones. Those upcoming milestones include completing SBP-101’s enrollment in the current Phase 1b trial in Q4 2020, reporting data from our Phase 1 trial in 1H 2021, initiating a randomized Phase 2 study in 1H 2021 while evaluating additional opportunities for SBP-101. Looking ahead, we’re focused on rapidly advancing SBP-101’s clinical development to create significant shareholder value.”

Based on interim data from our Phase I trial, SBP-101 demonstrated a 54% objective response rate in combination with gemcitabine & abraxane (G&A); more than double historical standard of care for metastatic pancreatic cancer with G&A.

We believe SBP-101 has the potential to expand into other cancers with known elevated levels of polyamine metabolism.

Upcoming
Milestones

  • Completion of enrollment in the expansion cohort targeting (Q4’20)
  • Data from phase 1 trial (1H’21) 
  • Conference presentations (1H’21 or 2H’21)
  • Initiation of randomized phase 2 study (1H’21)


Third Quarter ended September 30, 2020 Financial Results

General and administrative expenses increased to $1.2 million in the third quarter of 2020, up from $0.6 million in the third quarter of 2019. The change in the third quarter is due primarily to increased employee compensation expense.

Research and development expenses increased to $0.8 million in the third quarter of 2020, up from $0.7 million in the third quarter of 2019. The change in the third quarter is due to increased spending on the company’s clinical study.

Operating expenses in the third quarter of 2020 were partially offset by a foreign currency exchange gain on the intercompany receivable balance; for the same quarter in 2019 other expense, net was primarily a foreign currency exchange loss.

Net loss in the third quarter of 2020 was $1.7 million, or $0.21 per diluted share, compared to a net loss of $1.4 million, or $0.23 per diluted share, in the third quarter of 2019.

Total cash was $10.9 million as of September 30, 2020. Total current assets were $11.4 million and current liabilities were $1.9 million as of the same date.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: November 12, 2020
Time: 4:30 PM Eastern Time
Toll Free: 877-407-9205
International: 201-689-8054

A replay of the call will be available from November 13, 2020 through November 26, 2020

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 38324

The call will also be available over the Internet and accessible at: 
https://www.webcaster4.com/Webcast/Page/2556/38324  

About SBP-101 

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in Sun BioPharma’s current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799.

About Sun BioPharma 

Sun BioPharma Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Sun BioPharma Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer. SBP-101 was invented by Raymond J. Bergeron, PhD, a Distinguished Professor Emeritus at the University of Florida. Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, the University of Rochester in New York, Scripps MD Anderson Cancer Center in San Diego, California, the University of Florida, the Austin Health Cancer Trials Centre in Melbourne, Australia, the Ashford Cancer Centre in Adelaide, Australia, the Blacktown Cancer and Haematology Centre in Sydney, Australia and the John Flynn Private Hospital in Tugun, Queensland, Australia. The company’s independent Data Safety Monitoring Board (DSMB) is Chaired by James Abbruzzese, MD, Professor of Medicine, and Chief, Division of Medical Oncology at Duke University School of Medicine. Professor David Goldstein, FRACP, Senior Staff Specialist at the Prince Henry & Prince of Wales Hospital / Cancer Care Centre in Sydney, Australia is Co-Chair of the DSMB. Further information can be found at: www.sunbiopharma.com. Sun BioPharma’s common stock is listed on The Nasdaq Stock Market LLC under the symbol SNBP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believes,” “
dedicated,”
“expects,” “intends,” “may,”
“milestone,”
or “plans.” Examples of forward-looking statements include, among others, statements we make regarding, potential effects of FDA Fast Track designation, future determinations of the characteristics of SBP-101 and its effectiveness, uses of proceeds from recent financings. Forward-looking statements are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete Phase 1 clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete enrollment in our current clinical trial; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors:

James Carbonara
Hayden IR
(646) 755-7412
[email protected]

Media:

Tammy Groene
Sun BioPharma, Inc.
(952) 479-1196
[email protected]

Sun
BioPharma, Inc

Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(In thousands, except share and per share amounts)

                           
                           
    Three months ended September 30,   Nine months ended September 30,  
      2020       2019     Percent Change     2020       2019     Percent Change  
Operating expenses:                          
General and administrative   $ 1,223     $ 622     96.6 %   $ 2,348     $ 1,505     56.0 %  
Research and development     773       720     7.4 %     1,805       1,578     14.4 %  
Operating loss     (1,996 )     (1,342 )   48.7 %     (4,153 )     (3,083 )   34.7 %  
                           
Other income (expense):                          
Interest expense     (3 )     (3 )   0.0 %     (12 )     (2,187 )   -99.5 %  
Other income     239       (219 )   -209.1 %     55       (287 )   -119.2 %  
Total other income (expense)     236       (222 )   -206.3 %     43       (2,474 )   -101.7 %  
                           
Loss before income tax benefit     (1,760 )     (1,564 )   12.5 %     (4,110 )     (5,557 )   -26.0 %  
                           
Income tax benefit     89       190     -53.2 %     222       331     -32.9 %  
                           
Net loss     (1,671 )     (1,374 )   21.6 %     (3,888 )     (5,226 )   -25.6 %  
Foreign currency translation adjustment (loss)     (246 )     202     -221.8 %     (164 )     219     -174.9 %  
Comprehensive Loss   $ (1,917 )   $ (1,172 )   63.6 %   $ (4,052 )   $ (5,007 )   -19.1 %  
                           
Basic and diluted net loss per share $ (0.21 )   $ (0.23 )   -8.7 %   $ (0.55 )   $ (0.97 )   -43.3 %  
Weighted average shares outstanding – basic and diluted     7,888,609       6,009,904     31.3 %     7,085,326       5,385,986     31.6 %  
                           

 

Sun BioPharma, Inc.

Consolidated Balance Sheets (unaudited)

(In thousands, except share amounts)

         
         
         
         
         
    September 30, 2020   December 31, 2019
ASSETS   (Unaudited)    
Current assets:        
Cash   $ 10,870     $ 2,449  
Prepaid expenses and other current assets     335       283  
Income tax receivable     228       361  
Total current assets     11,433       3,093  
Other noncurrent assets     52       51  
Total assets   $ 11,485     $ 3,144  
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable   $ 422     $ 597  
Accrued expenses     632       304  
Term debt     37       116  
Payroll protection plan loan     103        
Unsecured promissory note payable     742       742  
Total current liabilities     1,936       1,759  
         
Stockholders’ equity:        
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2020 and December 31 2019            
Common stock, $0.001 par value; 100,000,000 authorized; 9,649,427 and 6,631,308 shares issued and outstanding as of September 30, 2020 and December 31, 2019 respectively     10       7  
Additional paid-in capital     54,544       42,331  
Accumulated deficit     (45,146 )     (41,258 )
Accumulated comprehensive income     141       305  
Total stockholders’ equity     9,549       1,385  
Total liabilities and stockholders’ equity   $ 11,485     $ 3,144  
         

Sun BioPharma, Inc.

Consolidated Statements of Cash Flows (unaudited)

(In thousands)

             
             
             
             
             
    Nine Months Ended September 30    
     2020     2019     
Cash flows from operating activities:            
Net loss   $ (3,888 )   $ (5,226 )    
Adjustments to reconcile net loss to net cash used in operating activities:            
Stock-based compensation     969       958      
Amortization of debt discount           2,061      
Amortization of debt issuance costs           12      
Non-cash interest expense           102      
Changes in operating assets and liabilities:            
Income tax receivable     133       44      
Prepaid expenses and other current assets     64       (12 )    
Accounts payable     (347 )     179      
Accrued liabilities     328       15      
Net cash used in operating activities     (2,741 )     (1,867 )    
             
Cash flows from financing activities:            
Proceeds from sale of common stock and warrants net of offering costs of $2     1,746       3,142      
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165     9,335            
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7           810      
Proceeds from exercise of warrants     52            
Proceeds from payroll protection loan     103            
Repayment of demand note           (25 )    
Repayments of term debt     (81 )     (82 )    
Net cash provided by financing activities     11,155       3,845      
             
Effect of exchange rate changes on cash     7       (6 )    
             
Net change in cash     8,421       1,972      
Cash at beginning of period     2,449       1,405      
Cash at end of period   $ 10,870     $ 3,377      
             
Supplemental disclosure of cash flow information:            
Cash paid during period for interest   $ 5     $ 11      
             
Supplemental disclosure of non-cash transactions:            
Warrants issued for future services   $ 228     $      
Warrants issued to underwriter   $ 353     $      
Cashless exercise of warrants   $ 8     $      
Amortization of warrants as offering costs   $ 114     $      
Beneficial conversion feature on convertible notes   $     $ 353      
Warrants issued with convertible notes   $     $ 419      
Common stock converted into convertible notes payable   $     $ 25      
Conversion of convertible notes payable and accrued interest into common stock   $     $ 2,281      
Issuance of unsecured promissory note in exchange of vendor accounts payable   $     $ 742      
             

 

Ethan Allen Increases Quarterly Cash Dividend

DANBURY, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or “the Company”) (NYSE:ETH) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.25 per share, payable on January 21, 2021 to shareholders of record at the close of business on January 7, 2021.

Farooq Kathwari, Chairman and CEO commented, “We are pleased that our Board made the decision to increase our regular quarterly dividend to $0.25, a 19% increase. These are unprecedent times. Our enterprise over the last 89 years has gone through the Great Depression, a World War, and several recessions including the Great Recession. We have come out stronger and more vibrant each time. We look forward to continuing our progress and remain cautiously optimistic.”

ABOUT ETHAN ALLEN

Ethan Allen Interiors Inc. (NYSE: ETH) is a leading interior design company, manufacturer and retailer in the home furnishings marketplace. Today the Company is a global luxury international home fashion brand that is vertically integrated from design through delivery, which affords its clientele a value proposition of style, quality and price. The Company provides complimentary interior design service to its clients and sells a full range of furniture products and decorative accents through a retail network of approximately 300 design centers in the United States and abroad as well as online at ethanallen.com. The design centers represent a mix of independent licensees and Company-owned and operated locations. The Company operates retail design centers located in the United States and Canada. The independently operated design centers are located in the United States, Asia, the Middle East and Europe. Ethan Allen owns and operates nine manufacturing facilities, including six manufacturing plants in the United States, two manufacturing plants in Mexico and one manufacturing plant in Honduras. Approximately 75% of its products are manufactured or assembled in these North American facilities.

For more information on Ethan Allen’s products and services, visit www.ethanallen.com.

Investor / Media Contact:  
Matt McNulty
Vice President, Finance
[email protected]

Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  • On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020
  • Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome after upcoming end-of-phase 2 meeting with FDA
  • Reported encouraging trial results from ARCADE open-label Phase 2 trial of soticlestat and ENDYMION long-term extension trial showing seizure frequency reductions over time in CDKL5 deficiency disorder and Dup15q syndrome and global improvements beyond motor seizure reduction in both CDKL5 deficiency disorder and Dup15q syndrome patients
  • In the ELEKTRA, ARCADE and ENDYMION trials, soticlestat appeared to be well-tolerated and demonstrated a safety profile consistent with the findings of previous studies with no new safety signals identified

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

“We are very pleased with the progress made on our pipeline this quarter, which was highlighted by encouraging results from both the ELEKTRA and the ARCADE Phase 2 trials of OV935,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “We look forward to advancing OV935 into a Phase 3 program for Dravet syndrome and Lennox-Gastaut syndrome next year after our end-of-phase 2 meeting with FDA. We are continuing to explore further clinical development opportunities in CDKL5 deficiency disorder, and Dup15q syndrome. Additionally, we remain on track to report topline data for the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome this quarter. Pending a successful NEPTUNE readout, OV101 has the potential to become the first-ever treatment approved for Angelman syndrome, a disorder affecting some 500,000 patients worldwide.”

Pipeline Updates and Recent Highlights

OV101 (gaboxadol) for Angelman Syndrome

  • Hosted an investor seminar to review multiple aspects of Angelman syndrome, including its biological mechanism, and Ovid’s OV101 (gaboxadol) development program. The seminar featured external experts discussing the role of tonic inhibition, treatment practice in Angelman syndrome, measurement scales, and what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome. Topline results from NEPTUNE are expected in the fourth quarter of 2020. Results, if positive, are intended to support registrational filings for OV101 in the U.S. and the rest of the world.
  • Presented three abstracts from the OV101 Angelman syndrome clinical development program at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress. The presentations included data on seizure and EEG outcomes from the Phase 2 STARS trial in individuals with Angelman syndrome; encore presentations of a study of caregiver insights in Angelman syndrome; and the utility of the Clinical Global Impression (CGI) scale for studying outcomes in neurodevelopmental conditions.

OV101 for Fragile X Syndrome

  • Presented an abstract from the OV101 Fragile X syndrome clinical development program at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress. The presentation included additional data and analyses from the Phase 2 ROCKET clinical trial of OV101 in individuals with Fragile X syndrome.

OV935 (soticlestat) for Rare Developmental and Epileptic Encephalopathies (DEE)

  • Announced that the double-blind, randomized placebo-controlled, Phase 2 ELEKTRA trial of soticlestat met its primary endpoint in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

° Results showed a 27.8% median reduction from baseline in convulsive seizure (DS cohort) and drop seizure (LGS cohort) frequency compared to a 3.1% median increase in patients taking placebo during the 12-week maintenance period (median placebo-adjusted reduction=30.5%; p=0.0007, based on the efficacy analysis set of 120 patients with seizure data in the maintenance period).

° DS and LGS patients treated with soticlestat demonstrated a 29.8% median reduction in convulsive seizure (DS cohort) and drop seizure (LGS cohort) frequency compared to 0.0% change in median seizure frequency in patients taking placebo during the full 20-week treatment period (titration plus maintenance) of the ELEKTRA study (placebo-adjusted reduction=25.1%; p=0.0024).

° In the ELEKTRA DS cohort (n=51), patients treated with soticlestat demonstrated a 33.8% median reduction in convulsive seizure frequency compared to a 7.0% median increase in patients taking placebo during the full 20-week treatment period of the study (median placebo-adjusted reduction in seizure frequency is 46.0%; p=0.0007).

° In the ELEKTRA LGS cohort (n=88), patients treated with soticlestat demonstrated a 20.6% median reduction in drop seizure frequency compared to a 6.0.% median reduction in patients taking placebo during the full 20-week treatment period of the study (median placebo-adjusted reduction in seizure frequency is 14.8%; p=0.1279).

  • Ovid and Takeda plan to meet with regulatory authorities regarding initiating a Phase 3 registrational program of soticlestat in individuals with DS or LGS.
  • Reported results from the Phase 2 ARCADE and ENDYMION OLE trials of OV935 in patients with CDKL5 deficiency disorder (CDD) and Dup15q syndrome showing seizure frequency reduction over time.

° In CDD patients (n=12), median motor seizure frequency reduction was 24% during the 12-week maintenance period in the ARCADE study, increasing to a 50% reduction in the 9-month interval in the ENDYMION long-term extension study in the five CDD patients who reached nine months of continuous treatment.

° In Dup15q patients (n=8), there was an increase in median motor seizure frequency in the ARCADE study during the 12-week maintenance period; however, longer-term data from the four Dup15q patients who reached nine months of continuous treatment showed a 74% reduction in median motor seizure frequency in the 9-month interval.

° Global Improvements were reported in both patient populations as assessed by the Clinical Global Impression of Change (CGI-C; investigator) and Caregiver Global Impression of Change (Care GI-C) scales. 67% of CDD patients and 38% of Dup15q were deemed markedly improved with minimal or no adverse events on the CGI-C scale after starting soticlestat treatment. For the Care-GI-C scale, 92% of CDD caregivers reported improvement on soticlestat treatment at the end of the ARCADE study, with 41% reporting much and very much improved.

° The ARCADE study exit interviews from the caregiver also give insight into improvements in verbal and nonverbal communication, alertness/level of engagement, overall quality of daily functioning and caregiver-chosen domains to suggest benefits of soticlestat treatment in domains beyond seizure control.

  • OV935 was generally well tolerated in the ELEKTRA, ARCADE and ENDYMION studies and demonstrated a safety profile consistent with the findings of previous studies with no new safety signals identified. Data reported are consistent with, and build upon, previous findings with OV935.
  • To date, all patients who have completed the Phase 2 ARCADE and ELEKTRA trials have rolled over into the ENDYMION open-label extension study.

Third Quarter 2020 Financial Results

  • Revenue was $6.9 million for the third quarter ended September 30, 2020, as compared to zero for the same period in 2019. The increase was due to the receipt of the $20 million upfront payment under the collaboration and license agreement with Angelini Pharma Rare Diseases AG, of which $6.9 million was recognized in the third quarter as revenue and $13.1 million was deferred.
  • As of September 30, 2020, cash and cash equivalents totaled $86.9 million. The Company strengthened its financial position with the completion of a public offering in August 2020, resulting in net proceeds of approximately $46.7 million.
  • Research and development expenses were $15.9 million for the third quarter ended September 30, 2020, as compared to $11.6 million for the same period in 2019. The increase of $4.3 million was primarily due to an increase in preclinical and clinical activities related to Ovid’s ongoing development programs.
  • General and administrative expenses were $7.4 million for the third quarter ended September 30, 2020, as compared to $5.2 million for the same period in 2019. The increase of $2.2 million was primarily due to an increase in professional service fees, compliance and pre-commercialization expenses, payroll and payroll-related expenses offset by a decrease in general office expenses.
  • The Company reported a net loss of $16.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.28, for the third quarter of 2020, as compared to a net loss of $16.6 million, or net loss per share attributable to common stockholders of $0.43, for the same period in 2019.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). For more information on Ovid, please visit www.ovidrx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: clinical and regulatory development of our programs, potential benefits of OV101, OV935 and our other research programs and the anticipated reporting schedule of clinical data and the potential benefits. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Condensed Consolidated Statements of Operations

(Unaudited)

    For the Three Months Ended September 30,   For the Three Months Ended September 30,   For the Nine  Months Ended September 30,   For the Nine  Months Ended September 30,
      2020       2019       2020       2019  
Revenue:                
License revenue   $ 6,914,034     $     $ 6,914,034     $  
Operating expenses:                
Research and development   $ 15,875,295     $ 11,597,633     $ 46,533,610     $ 30,052,432  
General and administrative     7,442,401       5,168,103       20,220,160       14,089,106  
Total operating expenses     23,317,696       16,765,736       66,753,770       44,141,538  
Loss from operations     (16,403,662 )     (16,765,736 )     (59,839,736 )     (44,141,538 )
Other (expense) income, net     (21,127 )     131,164       833,661       649,504  
Net loss   $ (16,424,789 )   $ (16,634,572 )   $ (59,006,075 )   $ (43,492,034 )
Net loss attributable to common stockholders   $ (16,424,789 )   $ (16,634,572 )   $ (59,006,075 )   $ (43,492,034 )
Net loss per share attributable to common stockholders, basic and diluted   $ (0.28 )   $ (0.43 )   $ (1.04 )   $ (1.21 )
Weighted-average common shares outstanding basic and diluted     59,406,215       38,504,825       56,586,640       35,872,441  





Selected Condensed Balance Sheet Data 


 (Unaudited)

    September 30,   December 31,
      2020     2019
         
Cash, cash equivalents and short-term investments   $ 86,866,275   $ 76,739,113
Working capital1     72,387,568     69,279,584
Total Assets     91,599,016     80,843,731
Total stockholder’s equity     63,643,038     70,023,561
             

1Working capital defined as current assets less current liabilities
           



Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
[email protected]

OR

Investors:

Argot Partners
Maeve Conneighton/Dawn Schottlandt
212-600-1902
[email protected]

Media:

Dan Budwick
1AB
[email protected]